The accompanying notes are an integral part of these audited consolidated financial statements.
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
1.
Incorporation and Operations and Going Concern
Stem
Holdings, Inc. (“Stem” or the “Company”) is a Nevada corporation incorporated on June 7, 2016, and is a leading
omnichannel, vertically-integrated cannabis branded products and technology company with state-of-the-art cultivation, processing, extraction,
retail, distribution, and delivery-as-a-service (DaaS) operations throughout the United States. Stem’s family of award-winning
brands includes TJ’s Gardens™, TravisxJames™, and Yerba Buena™ flower and extracts; Cannavore™ edible confections;
and e-commerce delivery platforms provide direct-to consumer proprietary logistics and an omnichannel UX (user experience)/CX (customer
experience).
The
Company purchases, improves, leases, operates, and invests in properties for use in the production, distribution and sales of cannabis
and cannabis-infused products licensed under the laws of the states of Oregon, Nevada, and California. As of September, 30, 2022, Stem
had ownership interests in 23 state issued cannabis licenses including nine (9) licenses for cannabis cultivation, three (3) licenses
for cannabis processing, two (2) licenses for cannabis wholesale distribution, three (3) licenses for hemp production and (6) cannabis
dispensary licenses.
The
Company has nine wholly-owned subsidiaries, including Stem Holdings Oregon, Inc., Stem Holdings IP, Inc., Opco, LLC, Stem Agri,
Inc., Stem Holdings Oregon Acquisitions 1, Corp., Stem Holdings Oregon Acquisitions 2, Corp., Stem Holdings Oregon Acquisitions 3,
Corp., Stem Holdings Oregon Acquisitions 4 Corp., 2336034 Alberta Ltd. Stem, through its subsidiaries, is currently in the process
of seeking the acquisition of entities or to be acquired by entities directly in the production and sale of cannabis. Driven
Deliveries, Inc., a former wholly-owned subsidiary, was sold during the quarter ended December 31, 2021 (see Note 3).
The
Company’s stock is publicly traded and is listed on the Canadian Securities Exchange under the symbol “STEM” and the
OTCQB exchange under the symbol “STMH”.
In
June 2021, the Company’s shareholders approved a proposal to amend the Company’s Articles of Incorporation to increase the
number of authorized common shares from 300,000,000 shares to 750,000,000 shares.
Going
Concern
On
September 30, 2022, the Company had approximate balances of cash and cash equivalents of $1.5
million, and working capital deficit of approximately $802
thousand, and an accumulated deficit of $133
million.
These
audited consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to
realize its assets and discharge its liabilities in the normal course of business.
The
United States federal government regulates drugs in large part through the Controlled Substances Act or CSA. Marijuana, which refers
to certain parts and derivatives of the cannabis plant, is classified as a Schedule I controlled substance. As a Schedule I controlled
substance, the federal Drug Enforcement Agency, or DEA, considers marijuana to have a high potential for abuse, no currently accepted
medical use in treatment in the United States, and a lack of accepted safety for use of the drug under medical supervision. According
to the U.S. federal government, cannabis having a concentration of tetrahydrocannabinol, or THC, greater than 0.3% is marijuana. Cannabis
with a THC content below 0.3% is classified as hemp. The scheduling of marijuana as a Schedule I controlled substance is inconsistent
with what we believe to be widely accepted medical uses for marijuana by physicians, researchers, customers, and others. Moreover, as
of December 31, 2021, and despite the conflict with U.S. federal law, at least 36 states, the District of Columbia, the Commonwealth
of the Northern Mariana Islands, Guam, Puerto Rico, and the U.S. Virgin Islands have legalized marijuana for medical use. Eighteen of
those states and the District of Columbia, the Commonwealth of the Northern Mariana Islands, and Guam have legalized the adult use of
cannabis for recreational purposes. In November 2020, voters in Arizona, Montana, New Jersey, and South Dakota voted by referendum to
legalize marijuana for adult use, and voters in Mississippi and South Dakota voted to legalize marijuana for medical use, although South
Dakota’s adult-use measure has been declared unconstitutional by the State Supreme Court. In 2021, the states of Connecticut, New
Mexico, New York, and Virginia enacted laws legalizing the adult use of cannabis.
Marijuana
is largely regulated at the state level in the United States. State laws regulating marijuana conflict with the CSA, making marijuana
use and possession federally illegal. Although certain states and territories of the United States authorize medical or adult-use marijuana
production and distribution by licensed or registered entities, under United States federal law, the possession, use, cultivation, and
transfer of marijuana and any related drug paraphernalia is illegal. Although our activities are compliant with the applicable state
and local laws in those states where we maintain such licenses, strict compliance with state and local laws with respect to cannabis
may neither absolve us of liability under United States federal law nor provide a defense to any federal criminal action that may be
brought against us.
In
2013, as more and more states began to legalize medical and/or adult-use marijuana, the federal government attempted to provide clarity
on the incongruity between federal law and these state-legal regulatory frameworks. Until 2018, the federal government provided guidance
to federal agencies and banking institutions through a series of DOJ memoranda. The most notable of this guidance came in the form of
a memorandum issued by former U.S. Deputy Attorney General James Cole on August 29, 2013, which we refer to as the Cole Memorandum.
The
Cole Memorandum offered guidance to federal agencies on how to prioritize civil enforcement, criminal investigations, and prosecutions
regarding marijuana in all states and quickly set a standard with which marijuana-related businesses would comply. The Cole Memorandum
put forth eight prosecution priorities:
1.
Preventing the distribution of marijuana to minors;
2.
Preventing revenue from the sale of marijuana from going to criminal enterprises, gangs, and cartels;
3.
Preventing the diversion of marijuana from states where it is legal under state law in some form to other states;
4.
Preventing the state-authorized marijuana activity from being used as a cover or pretext for the trafficking of other illegal drugs or
other illegal activity;
5.
Preventing violence and the use of firearms in the cultivation and distribution of marijuana;
6.
Preventing drugged driving and the exacerbation of other adverse public health consequences associated with marijuana use;
7.
Preventing the growing of marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana production
on public lands; and
8.
Preventing marijuana possession or use on federal property.
On
January 4, 2018, former United States Attorney General Sessions rescinded the Cole Memorandum by issuing a new memorandum to all United
States Attorneys, which we refer to as the Sessions Memo. Rather than establishing national enforcement priorities particular to marijuana-related
crimes in jurisdictions where certain marijuana activity was legal under state law, the Sessions Memo simply rescinded the Cole Memorandum
and other Department of Justice memorandums providing prosecutorial guidance on state and tribally authorized medical and adult-use cannabis
activities and instructed that “[i]n deciding which marijuana activities to prosecute... with the [DOJ’s] finite resources,
prosecutors should follow the well- established principles that govern all federal prosecutions.” Namely, these include the seriousness
of the offense, history of criminal activity, deterrent effect of prosecution, the interests of victims, and other principles.
On
January 21, 2021, Joseph R. Biden, Jr. was sworn in as President of the United States. President Biden’s Attorney General, Merrick
Garland, was confirmed by the United States Senate on March 10, 2021. It is not yet known whether the Department of Justice, under President
Biden and Attorney General Garland, will re-adopt the Cole Memorandum or announce a substantive marijuana enforcement policy. During
his Senate confirmation, Merrick Garland told Senator Cory Booker (D-NJ), “It does not seem to me useful the use of limited resources
that we have to be pursuing prosecutions in states that have legalized and are regulating the use of marijuana, either medically or otherwise.”
Such statements are not official declarations or policies of the DOJ and are not binding on the DOJ, any United States Attorney, or the
United States federal courts. Substantial uncertainty regarding United States federal enforcement remains. To date, there have been no
new federal cannabis memorandums issued by the Biden Administration or any published change in federal enforcement policy.
Nonetheless,
there is no guarantee that state laws legalizing and regulating the sale and use of marijuana will not be repealed or overturned or that
local government authorities will not limit the applicability of state laws within their respective jurisdictions. Unless and until the
United States Congress amends the CSA with respect to marijuana (and as to the timing or scope of any such potential amendments, there
can be no assurance), there is a risk that federal authorities may enforce current U.S. federal law. Currently, in the absence of uniform
federal guidance, as had been established by the Cole Memorandum, enforcement priorities are determined by respective United States Attorneys.
As
an industry best practice, despite the rescission of the Cole Memorandum, we abide by the following standard operating policies and procedures,
which are designed to ensure compliance with the guidance provided by the Cole Memorandum:
1.
Continuously monitor our operations for compliance with all licensing requirements as established by the applicable state, county, municipality,
town, township, borough, and other political/administrative divisions;
2.
Ensure that our cannabis-related activities adhere to the scope of the licensing obtained (for example: in the states where cannabis
is permitted only for adult-use, the products are only sold to individuals who meet the requisite age requirements);
3.
Implement policies and procedures to prevent the distribution of our cannabis products to minors;
4.
Implement policies and procedures in place to avoid the distribution of the proceeds from our operations to criminal enterprises, gangs,
or cartels;
5.
Implement an inventory tracking system and necessary procedures to reliably track inventory and prevent the diversion of cannabis or
cannabis products into those states where cannabis is not permitted by state law or across any state lines in general;
6.
Monitor the operations at our facilities so that our state-authorized cannabis business activity is not used as a cover or pretense for
trafficking of other illegal drugs or engaging in any other illegal activity; and
7.
Implement quality controls so that our products comply with applicable regulations and contain necessary disclaimers about the contents
of the products to avoid adverse public health consequences from cannabis use and discourage impaired driving.
In
addition, we frequently conduct background checks to confirm that the principals and management of our operating subsidiaries are of
good character and have not been involved with other illegal drugs, engaged in illegal activity or activities involving violence, or
the use of firearms in the cultivation, manufacturing, or distribution of cannabis. We also conduct ongoing reviews of the activities
of our cannabis businesses, the premises on which they operate, and the policies and procedures related to the possession of cannabis
or cannabis products outside of the licensed premises.
Moreover,
in recent years, certain temporary federal legislative enactments that protect the medical marijuana and hemp industries have also been
in effect. For instance, certain marijuana businesses receive a measure of protection from federal prosecution by operation of temporary
appropriations measures that have been enacted into law as amendments (or “riders”) to federal spending bills passed by Congress
and signed by Presidents Obama, Trump, and, most recently, President Biden. For instance, in the Appropriations Act of 2015, Congress
included a budget “rider” that prohibits DOJ from expending any funds to enforce any law that interferes with a state’s
implementation of its own medical marijuana laws. The rider originally known as the “Rohrbacher-Farr” Amendment after its
original lead sponsors is now known as the “Joyce” Amendment after its current sponsor. Originally, a Republican-controlled
House and Democratic-controlled Senate passed the Rohrbacher-Farr Amendment. The bill was “a bipartisan appropriations measure
that looks to prohibit the DEA from spending funds to arrest state-licensed medical marijuana patients and providers.” Subsequently,
the rider t has been included in multiple budgets passed by successive Congresses controlled by both major political parties. Most recently,
on February 18, 2022, the Amendment was renewed through the signing of an additional stopgap spending bill, H.R.6617 - Further Additional
Extending Government Funding Act, effective through March 11, 2022. While the Amendment has been included in successive appropriations
legislation or resolutions since 2015, its inclusion or non-inclusion is subject to political change.
Notably,
Joyce Amendment has applied only to medical marijuana programs and has not provided the same protections to enforcement against adult-use
activities. If the Amendment is no longer in effect, the risk of federal enforcement and override of state marijuana laws would increase.
In
December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China, and has since spread to several other
countries, including the United States. On June 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition,
as of the time of the filing of this Annual Report on Form 10-K, several states in the United States have declared states of emergency,
and several countries around the world, including the United States, have taken steps to restrict travel. The existence of a worldwide
pandemic, the fear associated with COVID-19, or any, pandemic, and the reactions of governments in response to COVID-19, or any, pandemic,
to regulate the flow of labor and products and impede the travel of personnel, may impact our ability to conduct normal business operations,
which could adversely affect our results of operations and liquidity. Disruptions to our supply chain and business operations disruptions
to our retail operations and our ability to collect rent from the properties which we own, personnel absences, or restrictions on the
shipment of our or our suppliers’ or customers’ products, any of which could have adverse ripple effects throughout our business.
If we need to close any of our facilities or a critical number of our employees become too ill to work, our production ability could
be materially adversely affected in a rapid manner. Similarly, if our customers experience adverse consequences due to COVID-19, or any
other, pandemic, demand for our products could also be materially adversely affected in a rapid manner. Global health concerns, such
as COVID-19, could also result in social, economic, and labor instability in the markets in which we operate. Any of these uncertainties
could have a material adverse effect on our business, financial condition, or results of operations.
These
conditions raise substantial doubt as to the Company’s ability to continue as a going concern. Should the United States Federal
Government choose to begin enforcement of the provisions under the “ACT”, the Company through its wholly owned subsidiaries
could be prosecuted under the “ACT” and the Company may have to immediately cease operations and/or be liquidated upon its
closing of the acquisition or investment in entities that engage directly in the production and or sale of cannabis.
Management
believes that the Company has access to capital resources through potential public or private issuances of debt or equity securities.
However, if the Company is unable to raise additional capital, it may be required to curtail operations and take additional measures
to reduce costs, including reducing its workforce, eliminating outside consultants, and reducing legal fees to conserve its cash in amounts
sufficient to sustain operations and meet its obligations. These matters raise substantial doubt about the Company’s ability to
continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might become necessary
should the Company be unable to continue as a going concern.
2.
Summary of Significant Accounting Policies
Basis
of Presentation
The
Company’s consolidated financial statements been prepared in accordance with accounting principles generally accepted in the United
States (“GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary.
All material intercompany accounts and transactions have been eliminated during the consolidation process. The Company manages its operations
as a single segment for the purposes of assessing performance and making operating decisions.
Use
of Estimates
The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the application
of accounting policies and the reported amounts of assets, liabilities, income, and expenses. The most significant estimates included
in these consolidated financial statements are those associated with the assumptions used to value equity instruments, valuation of its
long live assets for impairment testing, valuation of intangible assets, and the valuation of inventory. These estimates and assumptions
are based on current facts, historical experience and various other factors believed to be reasonable given the circumstances that exist
at the time the financial statements are prepared. Actual results may differ materially and adversely from these estimates. To the extent
there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Reclassifications
Certain
amounts in the Company’s consolidated financial statements for prior periods have been reclassified to conform to the current period
presentation. These reclassifications have not changed the results of operations of prior periods.
Principles
of Consolidation
The
Company’s policy is to consolidate all entities that it controls by ownership of a majority of the outstanding voting stock. In
addition, the Company consolidates entities that meet the definition of a variable interest entity (“VIE”) for which it is
the primary beneficiary. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly
impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits
from the entity that could potentially be significant to the entity. For consolidated entities that are less than wholly owned, the third
party’s holding of equity interest is presented as noncontrolling interests in the Company’s Consolidated Balance Sheets
and Consolidated Statements of Changes in Stockholders’ Equity. The portion of net loss attributable to the noncontrolling interests
is presented as net loss attributable to noncontrolling interests in the Company’s Consolidated Statements of Operations.
The
accompanying consolidated financial statements include the accounts of Stem Holdings, Inc. and its wholly owned subsidiaries, Stem Holdings
Oregon, Inc., Stem Holdings IP, Inc., Opco, LLC, Stem Holdings Agri, Inc., Stem Oregon Acquisitions 2 Corp., Stem Oregon Acquisitions
3 Corp., Stem Oregon Acquisitions 4 Corp., 7LV USA Corporation, and Stem Oregon Acquisitions 1 Corp., and Driven Deliveries, Inc., which
was subsequently divested. In addition, the Company has consolidated YMY Ventures, WCV, LLC and NVD RE, Inc. under the variable interest
requirements.
Cash
and Cash Equivalents
The
Company considers all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents.
Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The
Company’s cash is primarily maintained in checking accounts. These balances may, at times, exceed the U.S. Federal Deposit Insurance
Corporation insurance limits. As of September 30, 2022, and 2021, the Company had no cash equivalents or short-term investments. The
Company has not experienced any losses on deposits of cash and cash equivalents.
Accounts
Receivable
Accounts
receivable is shown on the face of the consolidated balance sheets, net of an allowance for doubtful accounts. The Company analyzes the
aging of accounts receivable, historical bad debts, customer creditworthiness and current economic trends, in determining the allowance
for doubtful accounts. The Company does not accrue interest receivable on past due accounts receivable. As of September 30, 2022, and
2021 the reserve for doubtful accounts was $79 for both periods.
Inventory
Inventory
is comprised of raw materials, finished goods and work-in-progress such as pre-harvested cannabis plants and by-products to be extracted.
The costs of growing cannabis including but not limited to labor, utilities, nutrition, and irrigation, are capitalized into inventory
until the time of harvest. The Company recorded an adjustment to reduce inventory to net realizable value of $88 and $0 as of September 30,
2022 and 2021, respectively.
Inventory
is stated at the lower of cost or net realizable value, determined using weighted average cost. Cost includes expenditures directly related
to manufacturing and distribution of the products. Primary costs include raw materials, packaging, direct labor, overhead, shipping and
the depreciation of manufacturing equipment and production facilities determined at normal capacity. Manufacturing overhead and related
expenses include salaries, wages, employee benefits, utilities, maintenance, and property taxes.
Net
realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion,
disposal, and transportation. At the end of each reporting period, the Company performs an assessment of inventory obsolescence to measure
inventory at the lower of cost or net realizable value. Factors considered in the determination of obsolescence include slow-moving or
non-marketable items.
Prepaid
Expenses and Other Current Assets
Prepaid
expenses consist of various payments that the Company has made in advance for goods or services to be received in the future. These prepaid
expenses include consulting, advertising, insurance, and service or other contracts requiring up-front payments.
Property
and Equipment
Property,
equipment, and leasehold improvements are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line
method over the estimated useful lives of the assets. Repairs and maintenance expenditures that do not extend the useful lives of related
assets are expensed as incurred.
Expenditures
for major renewals and improvements are capitalized, while minor replacements, maintenance, and repairs, which do not extend the asset
lives, are charged to operations as incurred. Upon sale or disposition, the cost and related accumulated depreciation are removed from
the accounts and any gain or loss is included in operations. The Company continually monitors events and changes in circumstances that
could indicate that the carrying balances of its property, equipment and leasehold improvements may not be recoverable in accordance
with the provisions of ASC 360, “Property, Plant, and Equipment.” When such events or changes in circumstances are present,
the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered
through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets,
the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. See “Note
3 – Property, Equipment and Leasehold Improvements”.
Property
and equipment are stated at cost less accumulated depreciation. Depreciation is provided on a straight-line method over the estimated
useful lives of the assets. The Company estimates useful lives as follows:
Schedule
of Estimated Useful Life of Assets
Buildings |
20
years |
Leasehold
improvements |
Shorter
of term of lease or economic life of improvement |
Furniture
and equipment |
5
years |
Signage |
5
years |
Software
and related |
5
years |
Impairment
of Long-Lived Assets
The
Company reviews the carrying value of its long-lived assets, which include property and equipment, for indicators of impairment whenever
events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. The Company considers
the following to be some examples of important indicators that may trigger an impairment review: (i) significant under-performance or
losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use
of assets or in the Company’s overall strategy with respect to the manner or use of the acquired assets or changes in the Company’s
overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant
decline in the Company’s stock price for a sustained period of time; and (vi) regulatory changes. The Company evaluates assets
for potential impairment indicators at least annually and more frequently upon the occurrence of such events. The Company does not test
for impairment in the year of acquisition of properties, as long as those properties are acquired from unrelated third parties.
The
Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the
related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying
amounts. In cases where estimated future net undiscounted cash flows are less than the carrying value, an impairment loss is recognized
equal to an amount by which the carrying value exceeds the fair value of the asset or asset group. Fair value is generally determined
using the assets expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined
to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values
of the long-lived assets are depreciated and amortized prospectively over the newly determined remaining estimated useful lives.
Equity
Method Investments
Investments
in unconsolidated affiliates are accounted for under the equity method of accounting, as appropriate. The Company accounts for investments
in limited partnerships or limited liability corporations, whereby the Company owns a minimum of 5.0% of the investee’s outstanding
voting stock, under the equity method of accounting. These investments are recorded at the amount of the Company’s investment and
adjusted each period for the Company’s share of the investee’s income or loss, and dividends paid.
During
the years ended September 30, 2022, and 2021, the Company recognized its share of investee losses of approximately $0 and $234 thousand,
respectively. The loss for the year ended September 30, 2021, was an aggregate of Community Growth Partners Holdings, Inc., (“CGP”)
of approximately $233 thousand and Tilstar Medical, LLC (“TIL”) of approximately $1 thousand.
Investments were impaired by $795 thousand and $2.2
million for the years ended September 30, 2022, and 2021 respectively.
Asset
Acquisitions
The
Company has adopted ASU 2017-01, which clarifies the definition of a business with the objective of adding guidance to assist entities
with evaluating whether transactions should be accounted for as businesses acquisitions. As a result of adopting ASU 2017-01, acquisitions
of real estate and cannabis licenses do not meet the definition of a business combination and were deemed asset acquisitions, and the
Company therefore capitalized these acquisitions, including its costs associated with these acquisitions.
Goodwill
and Intangible Assets
Goodwill.
Goodwill represents the excess acquisition cost over the fair value of net tangible and intangible assets acquired. Goodwill is not
amortized and is subject to annual impairment testing on or between annual tests if an event or change in circumstance occurs that would
more likely than not reduce the fair value of a reporting unit below its carrying value. In testing for goodwill impairment, the Company
has the option to first assess qualitative factors to determine whether the existence of events or circumstances lead to a determination
that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality
of events and circumstances, the Company concludes that it is not more likely than not that the fair value of a reporting unit is less
than its carrying amount, then performing the two-step impairment test is not required. If the Company concludes otherwise, the Company
is required to perform the two-step impairment test. The goodwill impairment test is performed at the reporting unit level by comparing
the estimated fair value of a reporting unit with its respective carrying value. If the estimated fair value exceeds the carrying value,
goodwill at the reporting unit level is not impaired. If the estimated fair value is less than the carrying value, further analysis is
necessary to determine the amount of impairment, if any, by comparing the implied fair value of the reporting unit’s goodwill to
the carrying value of the reporting unit’s goodwill. Goodwill impairment expense of $5.9 million and $0 was incurred for the years ended September 30, 2022, and 2021 respectively.
Intangible
Assets. Intangible assets deemed to have finite lives are amortized on a straight-line basis over their estimated useful lives, where
the useful life is the period over which the asset is expected to contribute directly, or indirectly, to our future cash flows. Intangible
assets are reviewed for impairment on an interim basis when certain events or circumstances exist. For amortizable intangible assets,
impairment exists when the carrying amount of the intangible asset exceeds its fair value. At least annually, the remaining useful life
is evaluated. Definite-lived intangible assets were impaired by $1,961 and $0 for the years ended September 30, 2022, and 2021 respectively.
An
intangible asset with an indefinite useful life is not amortized but assessed for impairment annually, or more frequently, when events
or changes in circumstances occur indicating that it is more likely than not that the indefinite-lived asset is impaired. Impairment
exists when the carrying amount exceeds its fair value. In testing for impairment, the Company has the option to first perform a qualitative
assessment to determine whether it is more likely than not that an impairment exists. If it is determined that it is not more likely
than not that an impairment exists, a quantitative impairment test is not necessary. If the Company concludes otherwise, it is required
to perform a quantitative impairment test. To the extent an impairment loss is recognized, the loss establishes the new cost basis of
the asset that is amortized over the remaining useful life of that asset, if any. Subsequent reversal of impairment losses is not permitted.
Business
Combinations
The
Company applies the provisions of ASC 805 in the accounting for acquisitions. ASC 805 requires the Company to recognize separately from
goodwill the assets acquired, and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date
is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the
liabilities assumed. While the Company uses its best estimates and assumptions to accurately apply preliminary value to assets acquired
and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, these estimates are inherently
uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date,
the Company records adjustments in the current period, rather than a revision to a prior period. Upon the conclusion of the measurement
period or final determination of the values of the assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments
are recorded in the consolidated statements of operations. Accounting for business combinations requires management to make significant
estimates and assumptions, especially at the acquisition date, including estimates for intangible assets, contractual obligations assumed,
restructuring liabilities, pre-acquisition contingencies, and contingent consideration, where applicable. Although the Company believes
the assumptions and estimates made have been reasonable and appropriate, they are based in part on historical experience and information
obtained from management of the acquired companies and are inherently uncertain. Unanticipated events and circumstances may occur that
may affect the accuracy or validity of such assumptions, estimates, or actual results.
Contingent
Consideration
The
Company accounts for “contingent consideration” according to FASB ASC 805, “Business Combinations” (“FASB
ASC 805”). Contingent consideration typically represents the acquirer’s obligation to transfer additional assets or equity
interests to the former owners of the acquiree if specified future events occur or conditions are met. FASB ASC 805 requires that contingent
consideration be recognized at the acquisition-date fair value as part of the consideration transferred in the transaction. FASB ASC
805 uses the fair value definition in Fair Value Measurements, which defines fair value as the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As defined in FASB
ASC 805, contingent consideration is (i) an obligation of the acquirer to transfer additional assets or equity interests to the former
owners of an acquiree as part of the exchange for control of the acquiree, if specified future events occur or conditions are met or
(ii) the right of the acquirer to the return of previously transferred consideration if specified conditions are met.
Warrant
Liability
The
Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value
at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair
value is recognized in the Company’s consolidated statements of operations. The fair value of the warrants issued by the Company
has been estimated using a Black Scholes model.
Embedded
Conversion Features
The
Company evaluates embedded conversion features within convertible debt to determine whether the embedded conversion feature(s) should
be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the statement
of operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is
evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company
records a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument
(offset to additional paid-in capital) and amortized to interest expense over the life of the debt.
Income
Taxes
The
provision for income taxes is determined in accordance with ASC 740, “Income Taxes”. The Company files a consolidated United
States federal income tax return. The Company provides for income taxes based on enacted tax law and statutory tax rates at which items
of income and expense are expected to be settled in our income tax return. Certain items of revenue and expense are reported for Federal
income tax purposes in different periods than for financial reporting purposes, thereby resulting in deferred income taxes. Deferred
taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established
when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has incurred net operating losses for
financial-reporting and tax-reporting purposes. As of September 30, 2022, and 2021, such net operating losses were offset entirely by
a valuation allowance.
The
Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely
than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately
realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company
classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively,
on the consolidated statements of operations.
In
December 2017, the Tax Cuts and Jobs Act (TCJA or the Act) was enacted, which significantly changes U.S. tax law. In accordance with
ASC 740, “Income Taxes”, the Company is required to account for the new requirements in the period that includes the date
of enactment. The Act reduced the overall corporate income tax rate to 21.0%, created a territorial tax system (with a one-time mandatory
transition tax on previously deferred foreign earnings), broadened the tax base and allowed for the immediate capital expensing of certain
qualified property.
Revenue
Recognition
The
Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an
entity determines are within the scope of Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (Topic
606), the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations
in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to
contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services
it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company
assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether
each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation when (or as) the performance obligation is satisfied.
Revenue
for the Company’s product sales has not been adjusted for the effects of a financing component as the Company expects, at contract
inception, that the period between when the Company’s transfers control of the product and when the Company receives payment will
be one year or less. Product shipping and handling costs are included in cost of product sales.
The
following policies reflect specific criteria for the various revenue streams of the Company:
Cannabis
Dispensary, Cultivation and Production
Revenue
is recognized upon transfer of retail merchandise to the customer upon sale transaction, at which time its performance obligation is
complete. Revenue is recognized upon delivery of product to the wholesale customer, at which time the Company’s performance obligation
is complete. Terms are generally between cash on delivery to 30 days for the Company’s wholesale customers.
The
Company’s sales environment is somewhat unique, in that once the product is sold to the customer (retail) or delivered (wholesale)
there are essentially no returns allowed or warranty available to the customer under the various state laws.
Delivery
1) |
Identify
the contract with a customer |
The
Company sells retail products directly to customers. In these sales there is no formal contract with the customer. These sales have commercial
substance and there are no issues with collectability as the customer pays the cost of the goods at the time of purchase or delivery.
2) |
Identify
the performance obligations in the contract |
The
Company sells its products directly to consumers. In this case these sales represent a performance obligation with the sales and any
necessary deliveries of those products.
3) |
Determine
the transaction price |
The
sales that are done directly to the customer have no variable consideration or financing component. The transaction price is the cost
that those goods are being sold for plus any additional delivery costs.
4) |
Allocate
the transaction price to performance obligations in the contract |
For
the goods that the Company sells directly to customers, the transaction price is allocated between the cost of the goods and any delivery
fees that may be incurred to deliver to the customer.
5) |
Recognize
revenue when or as the Company satisfies a performance obligation |
For
the sales of the Company’s own goods the performance obligation is complete once the customer has received the product.
Leases
On
October 1, 2020, the Company adopted ASC 842 and elected to apply the new standard at the adoption date and recognize a cumulative effect
as an adjustment to retained earnings. Upon calculation the effect on retained earnings was immaterial and no adjustment was deemed necessary.
Leases with an initial term of twelve months or less are not recorded on the balance sheet. For lease agreements entered into or reassessed
after the adoption of Topic 842, we combine the lease and non-lease components in determining the lease liabilities and right of use
(“ROU”) assets.
Our
lease agreements generally do not provide an implicit borrowing rate; therefore, an internal incremental borrowing rate is determined
based on information available at lease commencement date for purposes of determining the present value of lease payments. We used the
incremental borrowing rate on September 30, 2022, for all leases that commenced prior to that date. In determining this rate, which is
used to determine the present value of future lease payments, we estimate the rate of interest we would pay on a collateralized basis,
with similar payment terms as the lease and in a similar economic environment.
Under
Topic 842, operating lease expense is generally recognized evenly over the term of the lease. Lease costs were $1,224 thousand and $599
thousand for the years ended September 30, 2022, and 2021, respectively. There was sublease rental income of $0 and $17 thousand, respectively
for the years ended September 30, 2022, and 2021. The Company has ten operating leases consisting with remaining lease terms ranging
from 4 months to 177 months.
Lease
Costs
Schedule of Lease Costs
| |
Year
Ended | |
| |
September
30, | |
| |
2022 | |
Components
of total lease costs: | |
| | |
Operating
lease expense | |
$ | 1,224 | |
Total
lease costs | |
$ | 1,224 | |
Lease
positions as of September 30, 2022
ROU
lease assets and lease liabilities for our operating leases were recorded in the consolidated condensed balance sheet as follows:
Schedule
of Right-of-Use Assets and Lease Liabilities
| |
September
30, 2022 | |
Assets | |
| |
Right
of use asset | |
$ | 6,874 | |
Total
assets | |
$ | 6,874 | |
| |
| | |
Liabilities | |
| | |
Operating
lease liabilities – short term | |
$ | 580 | |
Operating
lease liabilities – long term | |
| 6,476 | |
Total
lease liability | |
$ | 7,056 | |
Lease
Terms and Discount Rate
Schedule
of Lease Terms and Discount Rate
Weighted average remaining lease term (in years) – operating lease | |
| 12.23 | |
Weighted average discount rate – operating lease | |
| 11.04 | % |
Cash
Flows
Schedule of Cash Flow Related to Lease
| |
Year Ended | |
| |
September 30, 2022 | |
Cash paid for amounts included in the measurement of lease liabilities: | |
| | |
ROU amortization | |
$ | 1,224 | |
Cash paydowns of operating liability | |
$ | (1,224 | ) |
Supplemental non-cash amounts of lease liabilities arising from obtaining: | |
| | |
ROU asset | |
$ | 6,874 | |
Lease Liability | |
$ | 7,056 | |
The
future minimum lease payments under the leases are as follows:
Schedule
of Future Minimum Lease Payments
| |
| 2022 | |
2023 | |
$ | 1,337 | |
2024 | |
| 1,147 | |
2025 | |
| 1,053 | |
2026 | |
| 1,033 | |
2027 | |
| 825 | |
Thereafter | |
| 8,345 | |
Total future minimum lease payments | |
| 13,740 | |
Less: Lease imputed interest | |
| (6,684 | ) |
Total | |
$ | 7,056 | |
Disaggregation
of Revenue
In
the year ended September 30, 2022, and 2021, revenue reported was primarily from the sale of cannabis and related products accounted
for under ASC 606.
The
following table illustrates our revenue by type related to the years ended September 30, 2022, and 2021:
Schedule of Disaggregation of Revenue
| |
2022 | | |
2021 | |
| |
September 30, | |
| |
2022 | | |
2021 | |
Revenue | |
| | |
| |
Wholesale | |
$ | 4,306 | | |
$ | 5,270 | |
Retail | |
| 14,867 | | |
| 18,432 | |
Rental | |
| - | | |
| 17 | |
Other | |
| 118 | | |
| 692 | |
Total revenue | |
| 19,291 | | |
| 24,411 | |
Discounts and returns | |
| (2,728 | ) | |
| (3,474 | ) |
Net Revenue | |
$ | 16,563 | | |
$ | 20,937 | |
Geographical
Concentrations
As
of September 30, 2022, the Company is primarily engaged in the production and sale of cannabis, which is only legal for recreational
use in 19 states and D.C., with lesser legalization, such as for medical use in an additional 21 states and D.C., as of the time of these
consolidated financial statements. In addition, the United States Congress has passed legislation, specifically the Agriculture Improvement
Act of 2018 (also known as the “Farm Bill”) that has removed production and consumption of hemp and associated products from
Schedule 1 of the Controlled Substances Act.
Cost
of Goods Sold
Cost
of sales represents costs directly related to manufacturing and distribution of the Company’s products. Primary costs include raw
materials, packaging, direct labor, overhead, shipping and handling and the depreciation of manufacturing equipment and production facilities.
Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance, and property taxes. The
Company recognizes the cost of sales as the associated revenues are recognized.
Fair
Value of Financial Instruments
As
defined in the authoritative guidance, fair value is the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date.
To
estimate fair value, the Company utilizes market data or assumptions that market participants would use in pricing the asset or liability,
including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable,
market corroborated or generally unobservable.
The
authoritative guidance establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (“Level 1” measurements)
and the lowest priority to unobservable inputs (“Level 3” measurements). The three levels of the fair value hierarchy are
as follows:
Level
1 — Observable inputs such as quoted prices in active markets at the measurement date for identical, unrestricted assets or liabilities.
Level
2 — Other inputs that are observable, directly, or indirectly, such as quoted prices in markets that are not active, or inputs
which are observable, either directly or indirectly, for substantially the full term of the asset or liability.
Level
3 — Unobservable inputs for which there is little or no market data and which the Company makes its own assumptions about how market
participants would price the assets and liabilities.
In
instances in which multiple levels of inputs are used to measure fair value, hierarchy classification is based on the lowest level input
that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular
input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
Stock-based
Compensation
The
Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options
issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price
of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest on
the grant date or over a one-year period.
The
Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating
the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application
of management’s judgment.
Expected
Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding
based on the simplified method, which is the half-life from vesting to the end of its contractual term.
Expected
Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.
Risk-Free
Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues
with an equivalent remaining term.
Expected
Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends
in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.
Effective
January 1, 2017, the Company elected to account for forfeited awards as they occur, as permitted by Accounting Standards Update (“ASU”)
2016-09. Ultimately, the actual expenses recognized over the vesting period will be for those shares that vested. Prior to making this
election, the Company estimated a forfeiture rate for awards at 0%, as the Company did not have a significant history of forfeitures.
Earnings
(Loss) per Share
ASC
260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”) with a reconciliation
of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic
EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common
stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the
entity.
Basic
net loss per share of common stock excludes dilution and is computed by dividing net loss by the weighted average number of shares of
common stock outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur
if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common
stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Since the Company has only
incurred losses, basic and diluted net loss per share is the same. Securities that could potentially dilute loss per share in the future
that were not included in the computation of diluted loss per share as of September 30, 2022, and 2021 are as follows:
Schedule of Computation of Diluted Loss
Potentially dilutive share-based instruments: | |
September 30, | | |
September 30, | |
| |
2022 | | |
2021 | |
Convertible notes | |
| 34,736,220 | | |
| 3,696,311 | |
Options to purchase common stock | |
| 5,518,185 | | |
| 7,140,447 | |
Unvested restricted stock awards | |
| - | | |
| - | |
Warrants to purchase common stock | |
| 65,783,059 | | |
| 62,965,833 | |
Anti-dilutive Securities | |
| 106,037,464 | | |
| 73,802,591 | |
Advertising
Costs
The
Company follows the policy of charging the cost of advertising to expense as incurred. Advertising expense was $266 thousand and $368 thousand
for the year ended September 30, 2022, and 2021, respectively.
Related
parties
Parties
are related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or
are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the
immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one
party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting
parties might be prevented from fully pursuing its own separate interests.
Segment
reporting
Operating
segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly
by the chief operating decision maker, or decision–making group in deciding how to allocate resources and in assessing performance.
The Company’s chief operating decision–maker is its chief executive officer. The Company currently operates in one segment.
Recent
Accounting Guidance
In
January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350)—Simplifying the Test for Goodwill Impairment.
ASU 2017-04 simplifies the accounting for goodwill impairments by eliminating the requirement to compare the implied fair value of goodwill
with its carrying amount as part of step two of the goodwill impairment test referenced in Accounting Standards Codification (“ASC”)
350, Intangibles - Goodwill and Other (“ASC 350”). As a result, an entity should perform its annual, or interim, goodwill
impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for
the amount by which the carrying amount exceeds the reporting unit’s fair value. However, the impairment loss recognized should
not exceed the total amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for annual reporting periods beginning
after December 15, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements
and related disclosures.
In
August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure
Requirements for Fair Value Measurement” (“ASU 2018-13”). ASU 2018-13 removes, modifies and adds certain disclosure
requirements in Topic 820 “Fair Value Measurement”. ASU 2018-13 eliminates certain disclosures related to transfers and the
valuations process, modifies disclosures for investments that are valued based on net asset value, clarifies the measurement uncertainty
disclosure, and requires additional disclosures for Level 3 fair value measurements. ASU 2018-13 is effective for the Company for annual
and interim reporting periods beginning January 1, 2020. The adoption of this standard did not have a material impact on the Company’s
consolidated financial statements and related disclosures.
In
February 2016, the FASB issued ASU No. 2016-02, Leases. The standard amends the existing lease accounting guidance and requires lessees
to recognize a lease liability and a right-of-use asset for all leases (except for short-term leases that have a duration of one year
or less) on their balance sheets. Lessees will continue to recognize lease expense in a manner similar to current accounting. For lessors,
accounting for leases under the new guidance is substantially the same as in prior periods but eliminates current real estate-specific
provisions and changes the treatment of initial direct costs. Entities are required to use a modified retrospective approach for leases
that exist or are entered into after the beginning of the earliest comparable period presented, with an option to elect certain transition
relief. Full retrospective application is prohibited. The standard was adopted as of October 1, 2020. As of September 30, 2022, the Company
recognized additional operating liabilities of approximately $7.1 million, with corresponding ROU assets of approximately $6.9 million.
In
June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments (“ASU 2016-13”). ASU 2016-13 provides guidance for recognizing credit losses on financial instruments based on
an estimate of current expected credit losses model. The amendments are effective for fiscal years beginning after December 15, 2019.
Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently
assessing the impact of the adoption of this ASU on its financial statements.
In
January 2020, the FASB issued ASU 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures
(Topic 323), and Derivative and Hedging (Topic 815), which clarifies the interaction of rules for equity securities, the equity method
of accounting, and forward contracts and purchase options on certain types of securities. The guidance clarifies how to account for the
transition into and out of the equity method of accounting when considering observable transactions under the measurement alternative.
The ASU is effective for annual reporting periods beginning after December 15, 2020, including interim reporting periods within those
annual periods, with early adoption permitted. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements
and related disclosures.
In
August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts
in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.
This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity’s own equity,
and also improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods beginning
after December 15, 2021 and interim periods within those annual periods and early adoption is permitted. We are currently evaluating
the impact of the new guidance on our consolidated financial statements.
3.
Discontinued Operations, Assets and Liabilities Held for Sale
Discontinued
Operations
On
December 15, 2021, pursuant to a Share Exchange Agreement, the Company sold Driven Deliveries and its subsidiaries to the shareholders
of Budee, Inc. in a transaction which the Company fully divested all of its interests in Driven Deliveries and all of its subsidiaries.
Included in the terms of the Share Exchange Agreement, the shareholder of Budee, Inc., and prior officer of Driven Deliveries returned
approximately 11.5 million shares of the Company’s common stock and assumed approximately $7.1 million of the Companies liabilities.
Notwithstanding, the Company was responsible for approximately $210,000 of accounts payable assumed in the acquisition of
Driven Deliveries , of which $130 thousand remains outstanding as of September 30, 2022.
The
following table presents the assets and liabilities associated with the divestiture of Driven Deliveries; Inc. as follows (in thousands):
Schedule
of Discontinued Operations of Assets and Liabilities
| |
December 15, | | |
September 30, | |
| |
2021 | | |
2021 | |
| |
| | |
| |
ASSETS | |
| | | |
| | |
Current assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 47 | | |
$ | 106 | |
Inventory | |
| 509 | | |
| 382 | |
Prepaid expenses and other current assets | |
| 242 | | |
| 887 | |
Total current assets | |
| 798 | | |
| 1,375 | |
| |
| | | |
| | |
Property and equipment, net | |
| 4 | | |
| 12 | |
Right of use asset | |
| 327 | | |
| 328 | |
Intangible assets, net | |
| 7,049 | | |
| 7,609 | |
Total assets | |
$ | 8,178 | | |
$ | 9,324 | |
| |
| | | |
| | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable and accrued expenses | |
| 7,551 | | |
| 5,967 | |
Short term notes and advances | |
| 3 | | |
| 7 | |
Settlement payable | |
| - | | |
| 92 | |
Acquisition notes payable | |
| - | | |
| 409 | |
Lease liability | |
| 218 | | |
| 218 | |
Total current liabilities | |
| 7,772 | | |
| 6,693 | |
| |
| | | |
| | |
Lease liability - long term | |
| 108 | | |
| 108 | |
Total liabilities | |
$ | 7,880 | | |
$ | 6,801 | |
The
total assets and total liabilities in the above table for the year ended September 30, 2021, are presented in the balance sheet as of
September 30, 2022, as Assets held for sale and Liabilities held for sale.
The
following table presents the operating results related to the divestiture of Driven Deliveries; Inc. (in thousands):
| |
2022 | | |
2021 | |
| |
Year Ended September 30, | |
| |
2022 | | |
2021 | |
| |
| | |
| |
Revenues | |
$ | 3,805 | | |
$ | 14,832 | |
Cost of goods sold | |
| 3,772 | | |
| 13,796 | |
Gross Profit | |
| 33 | | |
| 1,036 | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
Consulting fees | |
| 4 | | |
| 115 | |
Professional fees | |
| 24 | | |
| 275 | |
General and administration | |
| 1,749 | | |
| 4,643 | |
Impairment expense | |
| - | | |
| 50,255 | |
Total operating expenses | |
| 1,777 | | |
| 55,288 | |
Loss from operations | |
| (1,744 | ) | |
| (54,251 | ) |
| |
| | | |
| | |
Other income (expenses) | |
| | | |
| | |
Interest expense | |
| (1 | ) | |
| - | |
Other income | |
| - | | |
| 155 | |
Total other income (expense) | |
| (1 | ) | |
| 155 | |
Net loss | |
$ | (1,745 | ) | |
$ | (54,096 | ) |
4.
Property, Plant & Equipment
Property
and equipment consist of the following (in thousands):
Schedule
of Property, Plant and Equipment
| |
September 30, | | |
September 30, | |
| |
2022 | | |
2021 | |
| |
| | |
| |
Land | |
$ | 1,151 | | |
$ | 1,451 | |
Automobiles | |
| 93 | | |
| 74 | |
Signage | |
| 19 | | |
| 19 | |
Furniture and equipment | |
| 2,590 | | |
| 3,033 | |
Leasehold improvements | |
| 3,532 | | |
| 3,474 | |
Buildings and property improvements | |
| 7,460 | | |
| 10,126 | |
Computer software | |
| 59 | | |
| 56 | |
Property and equipment, gross | |
| 14,904 | | |
| 18,233 | |
Accumulated depreciation | |
| (5,815 | ) | |
| (5,635 | ) |
Property and equipment, net | |
$ | 9,089 | | |
$ | 12,598 | |
Depreciation
expense was approximately $1.61 million and $1.93 million for the years ended September 30, 2022, and 2021, respectively. Depreciation
expense is included in general and administrative expense.
5.
Inventory
Inventory
consists of the following (in thousands):
Schedule
of Inventory
| |
September
30, | | |
September
30, | |
| |
2022 | | |
2021 | |
| |
| | |
| |
Raw
materials | |
$ | 569 | | |
$ | 866 | |
Work-in-progress | |
| 450 | | |
| 543 | |
Finished
goods | |
| 1,656 | | |
| 1,717 | |
Total
Inventory | |
$ | 2,675 | | |
$ | 3,126 | |
Raw
materials and work-in-progress include the costs incurred for cultivation materials and live plants. Finished goods consists of cannabis
products sent to retail locations or ready to be sold. No inventory reserve was recorded for the years ended September 30, 2022, and
2021 due to management’s assessment of the inventory on hand.
6.
Prepaid expenses and other current assets
Prepaid
expenses and other current assets are assets and payments previously made, that benefit future periods. The balance as of September
30, 2022, includes the Employee Retention Tax Credit (“ERTC”) program from the U.S Treasury, as part of the COVID-19
stimulus package. During the fiscal year ended September 30, 2021, the Company applied for certain ERTC credits in the approximate
amount of $5.1
million, which is reflected within the Statement of Operations as a reduction to general and administration expense. The remaining
balance of the ERTC receivable was approximately $201
thousand as of September 30, 2022.
Prepaid
and other current assets comprised of the following:
Schedule
of Prepaid Expenses and Other Current Assets
| |
September 30, | | |
September 30, | |
| |
2022 | | |
2021 | |
| |
| | |
| |
Prepaid expenses | |
$ | 538 | | |
$ | 732 | |
ERTC credits | |
| 201 | | |
| 605 | |
Deposits and other current assets | |
| 190 | | |
| 850 | |
| |
| | | |
| | |
Total prepaid expenses and other current assets | |
$ | 929 | | |
$ | 2,187 | |
7.
Equity method investments
Tilstar
Medical, LLC
In
April 2019, the Company entered into an agreement to acquire 48% of the membership interest of Tilstar Medical, LLC (“TIL”).
TIL is a startup operation located in Laurel, Maryland and owns a project management company which assists in procuring licenses for
the production and sale of cannabis. The purchase price for the 48% interest was $550,000 to capitalize TIL which under the operating
agreement occurs upon the execution of the agreement. As of September 30, 2019, the Company had funded the $550,000 and accounted for
its investment using the equity method of accounting. The Company was not made aware at time of its investment in the type and magnitude
of expenses that would be funded with its investment capital and is currently in the process of renegotiating the terms of the operating
agreement. During the year ended September 30, 2019, Tilstar Medical along with its partner, Stem Holdings, Inc. received a letter from
the Maryland Medical Cannabis commission with notification that we received stage one pre-approval for a processor license. The Companies
application ranked amongst the top nine highest scoring applications for a medical cannabis processor license. Final awards will be issued
during calendar year 2021. During the years ended September 30, 2022 and 2021, the Company recognized minimal losses on investments related
to TIL. During the year ended September 30, 2022, the Company recorded impairment expense of approximately $288,000 related to its investment
in TIL.
Community
Growth Partners, Inc
On
January 6, 2020, the
Company issued a convertible promissory note to Community Growth Partners Holdings, Inc., (“CGS”) which acted as a line
of credit. Subject to the terms and conditions of the note, CGS promised to pay the Company all of the outstanding principal
together with interest on the unpaid principal balance upon the date that is twelve months after the effective date and was payable
as follows: (a)The Company agreed to make several loans to CGS from time to time upon request of CGS in amounts not to exceed the
principal sum of $2,000,000,
(b) Payment of principal and interest shall be immediately available funds, (c) This note may be prepaid in whole or in part at any
time without premium or penalty. Any partial prepayment shall be applied against the principal amount outstanding, (d) The unpaid
principal amount outstanding under this note shall bear interest commencing upon the first advance at the rate of 10% per annum
through the maturity date, calculated on the basis of a 365-day, until the entire indebtedness is fully paid, Upon the closing of a
$2,000,000
financing by the Company, all of the principal and interest shall automatically convert into equity shares of CGS at the price
obtained by the qualified financing. As of September 30, 2020, a portion of the note was converted into 7%
equity. In March 2021, the balance of a note receivable was converted into an additional 6%
equity leaving an equity investment of 13%.
As of the year ended September 30, 2022, pursuant to a secondary stock purchase agreement, the Company sold its note receivable and
equity investment in CGS in consideration for $1.65
million in cash, and recorded a gain of $488 thousand for the year ended September 30, 2022.
8.
Note Receivable
On
January 4, 2020, the Company issued a $355,000 promissory note to Community Growth Partners Holdings, Inc., (“CGS”). CGS
is a cannabis license holder in Massachusetts. Subject to the terms and conditions of the note, CGS promises to pay the Company all of
the outstanding balance together with interest the date that is six months after the opening of the Great Barrington Dispensary which
was opened September 2020. Pursuant to a note purchase agreement dated April 13, 2022, the Company sold the note for $150,000 thousand
simultaneous with its equity investment in CGS in consideration for $1.65 million in cash.
On
January 6, 2020, the Company issued a convertible non-negotiable revolving credit promissory note up to $2,500,000 with a four-year term
to CGS. Subject to the terms and conditions of the note, CGS promises to pay the Company the lesser of $2,500,000 or the aggregate unpaid
principal amount of the loan. In the period of January 2020 through August 2020 the Company advanced $899,700 related to the note. In
September 2020, the Company converted $480,182 of the balance into approximately 7% ownership in CGS. In March 2021, the Company converted
the remaining balance plus accrued interest of $30,000 into an additional 6% ownership interest in CGS. As of the year ended September
30, 2022, pursuant to a secondary stock purchase agreement, the Company sold its equity investment in CGS in consideration for $1.65
million in cash.
In
September 2020 a former employee received funds on behalf of the Company. On October 1, 2020, the Company executed a $14 thousand
promissory note to memorialize and structure a plan to receive the funds from the individual. The note was non-interest bearing and
was to be paid in equal monthly installments over an eighteen-month term
with a maturity date of March
1, 2022. As of September 30, 2022, and
September 30, 2021, the principal balance of the note was $0 and
$3
thousand, respectively.
On
October 1, 2020, the Company issued a $100,000 promissory note to Bushman Holdings, Inc., (“BHI”) BHI is a CBD Cannabis holding
company in Florida. During the year ended September 30, 2021, the Company issued additional promissory notes totaling $210,000. Subject
to the terms and conditions of the notes, BHI promised to pay the Company all outstanding balances on or before January 1, 2022. The
Company has determined that the note is uncollectible and recognized bad debt expense of $310,000 for the year ended September 30, 2021.
On
April 5, 2021, the Company issued a $250,000 non-negotiable convertible promissory note (“Note”) to Blake, Inc. The Note
has a maturity date which is six months after the close of the Arkannabis, a Colorado grow facility. The note has annual interest rate
of 5.75%. Per the terms of the note, the principal balance and related interest shall be made in immediately available funds in lawful
currency. The terms of the note call for automatic conversion upon the closing of the Arkannabis business of the outstanding principal
and interest on this Note and will convert into that number of shares of the equity securities equivalent to a non-dilutive 12.5% of
the issued and outstanding shares of the Arkannabis business. The Company has determined that the note is uncollectible and recognized
bad debt expense of $257,010 for the year ended September 30, 2021.
9.
Consolidated Asset Acquisitions
West
Coast Ventures
On
March 29, 2019, the Company entered into a definitive agreement to acquire Western Coast Ventures, Inc. (“WCV”). At the time
of acquisition, WCV was a shell with cash of $2,000,000 and a 51% ownership with ILCA Holdings, Inc. (“ILCA”). At the time
of acquisition of WCV, ILCA was also a shell with no operations, which has been issued a limited Conditional Use Permit for a Marijuana
Production Facility (a “MPF”) by the City of San Diego, California, which will only be granting a total of 40 MPFs. As consideration
for the acquisition, the Company issued 2,500,000 shares of its common stock, with a fair value of approximately $4.4 million or $1.47
per share, the Company’s closing stock price on March 29, 2019. The Company recorded $2.0 million of cash acquired and a $2.4 million
investment in ILCA. During the year ended September 30, 2021 the Company determined the investment in ILCA was impaired and recognized
an impairment expense of $2.2 million for the year ended September 30, 2021.
Michigan
RE 1
On
January 4, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with Michigan RE 1, Inc.
(“MRE1”) pursuant to a private placement offering of up to an aggregate amount of $510 comprising
up to 510 shares
of MRE1’s common stock which represents 51%
ownership by the Company. On January 5, 2021, the Company was party to an Asset Purchase Agreement between Leoni Wellness, LLC
(“Seller”) and Organic Guyz, LLC (“Purchaser”) whereas the Seller is engaged in the recreational cannabis
business and the Purchaser desired to purchase the local municipal license to operate an adult use retailer in the City of
Kalamazoo, Michigan. The purchase price to be paid by the Purchaser was $400,000. As
of September 30, 2021, the buildout of the Michigan retail dispensary had begun, however the project has been delayed due to
Department of Zoning and Planning coding issues. During the year ended September 30, 2022, due to related religious reasons, the
Department of Zoning and Planning had indicated that it would not issue a license, therefore, impairing this investment in full in the amount of $507 thousand.
Kaya
Holdings, Corp.
On
April 13, 2021, the Company executed an Investors’ Rights Agreement in conjunction with a Subscription Agreement with Kaya Holdings,
Corp. The Company purchased 2,875,000 shares of Class B common stock of Kaya Holdings, Corp for a total investment of $230,000. In addition
to the purchased Class B shares, the Company received 500,000 founder Class B shares resulting in a total of 3,375,000 Class B shares.
For the year ended September 30, 2022, the Company, pursuant to a securities purchase agreement sold all of these shares to a third party
for $200,000, incurring a loss of $30,000.
10.
Non-Controlling Interests
Non-controlling
interests in consolidated entities are as follows (in thousands):
Schedule of Non-Controlling Interests in Consolidated Entities
| |
As of September 30, 2021 | |
| |
NCI Equity Share | | |
Net Loss Attributable to NCI | | |
NCI in Consolidated Entities | | |
Non-Controlling Ownership % | |
NVD RE Corp. | |
$ | 587 | | |
$ | (34 | ) | |
$ | 553 | | |
| 36.2 | % |
Western Coast Ventures, Inc. | |
| 1,052 | | |
| (210 | ) | |
| 842 | | |
| 49.0 | % |
YMY Ventures, Inc. | |
| 243 | | |
| 56 | | |
| 299 | | |
| 50.0 | % |
Michigan RE 1, Inc. | |
| - | | |
| (54 | ) | |
| (54 | ) | |
| 49.0 | % |
| |
$ | 1,882 | | |
$ | (242 | ) | |
$ | 1,640 | | |
| | |
| |
As of September 30, 2022 | |
| |
NCI Equity Share | | |
Net Loss Attributable to NCI | | |
NCI in Consolidated Entities | | |
Non-Controlling Ownership % | |
NVD RE Corp. | |
$ | 553 | | |
$ | (37 | ) | |
$ | 516 | | |
| 36.2 | % |
Western Coast Ventures, Inc. | |
| 842 | | |
$ | (3 | ) | |
| 839 | | |
| 49.0 | % |
YMY Ventures, Inc. | |
| 299 | | |
$ | 30 | | |
| 329 | | |
| 50.0 | % |
Michigan RE 1, Inc. | |
| (54 | ) | |
$ | (152 | ) | |
| (206 | ) | |
| 49.0 | % |
| |
$ | 1,640 | | |
$ | (162 | ) | |
$ | 1,478 | | |
| | |
11.
Business Combination
Driven
Deliveries, Inc.
In
December 2020, the Company, through an Agreement and Plan of Merger became the parent of an 100% wholly owned subsidiary Driven Deliveries,
Inc., (“DRVD”, “Driven” or “Driven Deliveries”), its subsidiaries, a publicly held corporation on
December 29, 2020. DRVD is an e-commerce and DaaS (delivery-as-a-service) provider with proprietary logistics and omnichannel UX/CX technology.
Driven utilizes its own fulfillment centers, drivers, and proprietary technology. Driven provides two service levels to its customers:
(i) an “Express” delivery with a limited product selection that is usually delivered within 90 minutes or less; and (ii)
a “Next Day” scheduled delivery from a larger selection of 500+ products from a Driven fulfillment center. In connection
with the acquisition, the Company issued 101,968,944 shares of common stock to the existing shareholders of Driven (“DRVD Shares”).
As part of the Acquisition, the Company assumed the Driven stock options outstanding on the closing of the acquisition in the amount
of 4,530,495. Accordingly, the Company has assumed 30,249,184 common share purchase warrants (the “Warrants”), exercisable
into shares at an average exercise price of $.45 per share. Following the completion of the acquisition, Driven became a wholly-owned
subsidiary of the Company.
The
table below shows the warrant liability and embedded derivative liability recorded in connection with the Driven convertible notes and
the subsequent fair value measurement during the year ended September 30, 2021 in USD, (in thousands):
Schedule
of Liabilities Measured at Fair Value
| |
Warrant Liability | | |
Derivative Liability | |
Balance as of September 30, 2020 | |
$ | - | | |
$ | - | |
Warrants acquired | |
| 9,000 | | |
| - | |
Warrants converted into equity | |
| (4,589 | ) | |
| - | |
| |
| | | |
| | |
Change in fair value | |
| (2,415 | ) | |
| - | |
Balance as of September 30, 2021 | |
$ | 1,996 | | |
$ | - | |
Purchase
Price Allocation
As
of December 29, 2020, the Company allocated the purchase consideration to the fair value of the assets acquired and liabilities assumed
as summarized in the table below (in thousands):
Consideration
Paid (in thousands)
Schedule of Purchasre Consideration to Fair value of assets Aquired and Liabilities Assumed
Consideration Paid (in thousands) | |
| | |
Estimated fair value of common stock issued | |
$ | 40,048 | |
Estimated fair value of warrants issued | |
| 9,000 | |
Estimated fair value of options issued | |
| 500 | |
Estimated fair value of debt assumed | |
| 4,389 | |
Total consideration paid | |
$ | 53,937 | |
| |
| | |
Assets acquired: (in thousands) | |
| | |
Cash and cash equivalents | |
$ | - | |
Fixed assets | |
| 47 | |
Other Assets | |
| 1,526 | |
Goodwill | |
| 11,740 | |
Intangible assets | |
| 47,900 | |
Total assets acquired | |
$ | 61,213 | |
| |
| | |
Liabilities assumed: (in thousands) | |
| | |
Accrued expenses and other current liabilities | |
| (7,276 | ) |
Total liabilities assumed | |
$ | (7,276 | ) |
Net assets acquired (in thousands) | |
$ | 53,937 | |
The
goodwill of $11,740,000 was not expected to be deductible for income tax expenses.
Based
on a review of long-lived tangible and intangible asset, and goodwill, an impairment expense of $52.5 million was recorded during the
fiscal year ended September 30, 2021.
On
December 17, 2021, pursuant to a Share Exchange Agreement, the Company sold Driven Deliveries and its subsidiaries to the shareholders
of Budee, Inc. in a transaction which STEM fully divested its interest in Driven Deliveries and its subsidiaries. Included in the terms
of the Share Exchange Agreement, the shareholders of Budee, and a prior officer of Driven Deliveries returned approximately 11.5 million
shares of the Company’s common stock and assumed approximately $7.9 million of the Company’s liabilities. Notwithstanding,
the Company was responsible for $210,753 of accounts payable assumed in the acquisition of Driven Deliveries. (see Note 3).
During
the year ended September 30, 2021, the Company also recorded adjustments for the elimination of other investments totaling $1.715 million.
Artifact
On
September 17, 2021, pursuant to an Agreement and Plan of Reorganization (“Agreement”) the Company acquired a marijuana processor
business and a marijuana retailer business located in Eugene, Oregon; a marijuana retailer business located in Salem, Oregon; and certain
intellectual property assets, including but not limited to the “ARTIFACT EXTRACTS” trademark that is used by the retail businesses
acquired in connection with the Agreement. In connection with the Agreement, the Company acquired fixed assets and intangible assets
in exchange for 8,209,178 common shares of the Company valued at $2,380,661 or $0.29 per share.
Purchase
Price Allocation
As
of September 17, 2021, the Company allocated the purchase consideration to the fair value of the assets acquired and liabilities assumed
as summarized in the table below (in thousands):
Schedule of Purchase Consideration to Fair value of assets Acquired and Liabilities Assumed
Purchase Consideration |
| |
| |
Stock Consideration | |
$ | 2,381 | |
| |
| | |
Total Purchase Consideration | |
$ | 2,381 | |
| |
| | |
Allocation of Purchase Consideration |
| |
| |
Working Capital | |
$ | 189 | |
| |
| | |
Fixed Assets | |
| 14 | |
| |
| | |
Customer Relationships | |
| 3 | |
| |
| | |
License | |
| 1,762 | |
| |
| | |
Tradename | |
| 206 | |
| |
| | |
Goodwill | |
| 207 | |
| |
| | |
Total Purchase Consideration | |
$ | 2,381 | |
The
goodwill of $207,000 is not expected to be deductible for income tax expenses.
The
following unaudited proforma condensed consolidated results of operations have been prepared as if the acquisition above occurred October
1, 2020.
Schedule
of Unaudited Proforma Information
| |
Year Ended | |
| |
September 30,
2021 | |
Revenue | |
$ | 43,821 | |
Net loss | |
$ | (75,427 | ) |
The
unaudited proforma condensed consolidated results of operations are not necessarily indicative of results that would have occurred had
the acquisitions occurred as of October 1, 2021, nor are they necessarily indicative of the results that may occur in the future.
12.
Intangible Assets, net
Intangible
assets as of September 2021, and 2020 (in thousands):
Schedule of Intangible Assets
| |
Estimated Useful Life | | |
Cannabis Licenses | | |
Tradename | | |
Customer Relationship | | |
Non-compete | | |
Technology | | |
Accumulated Amortization | | |
Net Carrying Amount | |
Balance as September 30, 2021 | |
| | | |
$ | 20,092 | | |
$ | 951 | | |
$ | 645 | | |
$ | 220 | | |
$ | 418 | | |
$ | (3,861 | ) | |
$ | 18,465 | |
YMY Ventures | |
| 15 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (49 | ) | |
| (49 | ) |
Western Coast Ventures, Inc. | |
| 15 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Yerba Buena | |
| 3-15 years | | |
| (1,238 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| 386 | | |
| (852 | ) |
Foothill (7LV) | |
| 15 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (523 | ) | |
| (523 | ) |
Driven Deliveries (See Note 3) | |
| 10-15 years | | |
| (9,315 | ) | |
| (413 | ) | |
| - | | |
| - | | |
| (413 | ) | |
| 2,533 | | |
| (7,608 | ) |
JV Retail 3 | |
| 3-15 years | | |
| (391 | ) | |
| (129 | ) | |
| - | | |
| - | | |
| - | | |
| 16 | | |
| (504 | ) |
JV Retail 4 | |
| 3-15 years | | |
| (391 | ) | |
| (129 | ) | |
| - | | |
| - | | |
| - | | |
| 18 | | |
| (502 | ) |
JV Extraction | |
| 10-15 years | | |
| (392 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| (21 | ) | |
| (413 | ) |
Other | |
| 5 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Balance as September 30, 2022 | |
| | | |
$ | 8,365 | | |
$ | 280 | | |
$ | 645 | | |
$ | 220 | | |
$ | 5 | | |
$ | (1,501 | ) | |
$ | 8,014 | |
Actual
amortization expense to be reported in future periods could differ from these estimates as a result of new intangible asset acquisitions,
changes in useful lives or other relevant factors or changes. Amortization expense for the years ended September 30, 2022, and 2021 was
$881 thousand and $3,460, respectively.
The
following table is a runoff of expected amortization in the following 5-year period as of September 30:
Schedule of Expected Amortization
| |
| | |
2023 | |
$ | 680 | |
2024 | |
| 680 | |
2025 | |
| 680 | |
2026 | |
| 680 | |
2027 | |
| 680 | |
Thereafter | |
| 4,614 | |
Intangible assets | |
$ | 8,014 | |
13.
Accounts payable and accrued expenses
Accounts
payable and accrued expenses consist of the following (in thousands):
Schedule of Accounts Payable and Accrued Expenses
| |
| | |
| |
| |
September 30, | | |
September 30, | |
| |
2022 | | |
2021 | |
Accounts payable | |
| 1,790 | | |
$ | 1,105 | |
Accrued credit cards | |
| 14 | | |
| 25 | |
Accrued interest | |
| 111 | | |
| 87 | |
Accrued payroll | |
| 109 | | |
| 713 | |
Accrued sales tax liability | |
| 120 | | |
| 148 | |
Other | |
| 166 | | |
| 469 | |
Total Accounts Payable and Accrued Expenses | |
$ | 2,310 | | |
$ | 2,547 | |
| |
| | | |
| | |
14.
Notes Payable and Advances
The
following table summarizes the Company’s short-term notes and advances, acquisition note payable, due to related party loans, and
long-term debt, mortgages as of September 30, 2022, and 2021:
Schedule of Short-term Notes and Advances
| |
| | |
| |
| |
September 30, | | |
September 30, | |
| |
2022 | | |
2021 | |
Equipment financing | |
$ | 20 | | |
$ | 30 | |
Insurance financing | |
| 230 | | |
| 261 | |
Promissory note | |
| 201 | | |
| 359 | |
Total notes payable and advances | |
$ | 451 | | |
$ | 650 | |
| |
| | | |
| | |
Current portion of long-term debt | |
$ | 1,000 | | |
$ | - | |
| |
| | | |
| | |
Long-term mortgages, net of current portion | |
| 1,225 | | |
| 2,100 | |
Total long-term debt, net of current portion | |
$ | 2,225 | | |
$ | 2,100 | |
Equipment
financing
Effective
April 29, 2018, the Company entered into a 36-month premium finance agreement in consideration for a John Deere Gator Tractor in the
principal amount of $15,710. The note bears no annual interest rate and requires the Company to make thirty-six monthly payments of $442
over the term of the note. As of September 30, 2022, and 2021, the obligation outstanding is $0. No amount was recorded for the premium
for the non-interest-bearing feature of the note as it was immaterial. The note was secured by the equipment financed.
Pursuant
to the Company’s acquisition of Yerba Buena the Company assumed a note payable obligation dated July 2017 related to a tractor
which had a 60-month premium finance agreement. The principal amount was $28,905. The note bears no annual interest rate and requires
the Company to make sixty monthly payments of $482 over the term of the note. No amount was recorded for the premium for the non-interest-bearing
feature of the note as it was immaterial. The note is secured by the equipment financed. As of September 30, 2022, the obligation outstanding
is $0.
January
2021, the Company entered into a promissory note in the amount of $27,880 for the acquisition of a truck. The promissory note bears an
interest rate of 13.29% per annum and is secured by the financed vehicle. The note has a sixty-month term with monthly payment of $642.
As of September 30, 2022, the balance outstanding is $20,465.
Insurance
financing
Effective
February 17, 2021, the Company entered into a 12-month premium finance agreement in partial consideration for an insurance policy in
the principal amount of $243,284. The note bears an annual interest rate of 7.46%. The Company paid $47,100 as a down payment on February
17, 2021, the note requires the Company to make 10 monthly payments of $17,835 over the remaining term of the note. In February 2022,
the total outstanding obligation was paid.
Effective
December 4, 2020, the Company entered into a 10-month premium finance agreement in partial consideration for an insurance policy in the
principal amount of $9,920. The note bears an annual interest rate of 12.8%. The Company paid $2,383 as a down payment on December 4,
2020, the note requires the Company to make 10 monthly payments of $754 over the remaining term of the note. As of September 30, 2022,
the obligation has been paid.
Effective
February 24, 2021, the Company entered into a 12-month premium finance agreement in partial consideration for an insurance policy in
the principal amount of $13,694. The note bears an annual interest rate of 7.369%. The Company paid $3,424 as a down payment on April
19, 2021, the note requires the Company to make 9 monthly payments of $1,199 over the remaining term of the note. As of September 30,
2022, the obligation has been paid.
Effective
April 10, 2021, the Company entered into a 12-month premium finance agreement for an insurance policy in the principal amount of $78,750.
The note bears an annual interest rate of 8.35%. The Company paid $15,750 as a down payment on May 10, 2021, the note requires the Company
to make 9 monthly payments of $7,271 over the remaining term of the note. As of September 30, 2022, the obligation has been paid.
Effective
April 17, 2021, the Company entered into a 12-month premium finance agreement for an insurance policy in the principal amount of $23,014.
The note bears an annual interest rate of 11.98%. The Company paid $4,871 as a down payment on March 16, 2021, the note requires the
Company to make 10 monthly payments of $1,814 over the remaining term of the note. As of September 30, 2022, the obligation outstanding
has been paid.
Effective
May 31, 2021, the Company entered into a 12-month premium finance agreement for an insurance policy in the principal amount of $8,906.
The note bears an annual interest rate of 10.25%. The Company paid $2,537 as a down payment on May 28, 2021, the note requires the Company
to make 9 monthly payments of $741 over the remaining term of the note. As of September 30, 2022, the obligation has been paid.
Effective
July 16, 2021, the Company entered into a 12-month premium finance agreement for an insurance policy in the principal amount of $11,830.
The note bears an annual interest rate of 1.06%. The Company paid $4,113 as a down payment in June 2021, the note requires the Company
to make 9 monthly payments of $771 over the remaining term of the note. As of September 30, 2022, the obligation has been paid.
Effective
July 17, 2021, the Company entered into a 12-month premium finance agreement for an insurance policy in the principal amount of $16,850.
The note bears an annual interest rate of 3.96%. The note requires the Company to make 12 monthly payments of $1,351 over the term of
the note. As of September 30, 2022, the obligation has been paid.
Effective
August 30, 2021, the Company entered into a 12-month premium finance agreement for an insurance policy in the principal amount of $58,899.
The note bears an annual interest rate of 7.99%. The Company paid $17,769 as a down payment on August 1, 2021, the note requires the
Company to make 9 monthly payments of $4,113 over the remaining term of the note. Additionally, effective August 30, 2021, the Company
entered into a 12-month premium finance agreement for an insurance policy in the principal amount of $94,116. The note bears an annual
interest rate of 11.26%. The Company paid $27,102 as a down payment on August 27, 2021, the note requires the Company to make 9 monthly
payments of $7,446 over the remaining term of the note. During the year ended September 30, 2022, a new location was added to the policy,
therefore, creating a new finance agreement requiring 7 payments of $12,188 which has been satisfied.
Effective
October 26, 2021, the Company entered into a 12-month premium finance agreement for an insurance policy in the principal amount of $10,411.
The note bears an annual interest rate of 10.65%. The Company paid $1,751 as a down payment in October 2021, the note requires the Company
to make 10 monthly payments of $866 over the remaining term of the note. As of September 30, 2022, the obligation has been paid.
Effective
February 9, 2022, the Company entered into a 12-month premium finance agreement in partial consideration for an insurance policy in the
principal amount of $430,657. The note bears an annual interest rate of 7.64%. The Company paid $86,131 as a down payment on February
14, 2022, the note requires the Company to make 10 monthly payments of $35,795 over the remaining term of the note. As of September 30,
2022, the obligation outstanding is $107,386.
Effective
February 24, 2022, the Company entered into a 12-month premium finance agreement in partial consideration for an insurance policy in
the principal amount of $17,551. The note bears an annual interest rate of 7.37%. The Company paid $18,033 as a down payment on February
24, 2022, the note requires the Company to make 10 monthly payments of $1,327 over the remaining term of the note. As of September 30,
2022, the obligation outstanding is $3,981.
Effective
April 6, 2022, the Company entered into a 12-month premium finance agreement in partial consideration for an insurance policy in the
principal amount of $29,060. The note bears an annual interest rate of 9.65%. The Company paid $5,812 as a down payment on April 6, 2022,
the note requires the Company to make 9 monthly payments of $2,697.47 over the remaining term of the note. As of September 30, 2022,
the obligation outstanding is $10,790.
Effective
May 23, 2022, the Company entered into a 12-month premium finance agreement in partial consideration for an insurance policy in the principal
amount of $7,599. The note bears an annual interest rate of 11.50%. The Company paid $2,121 as a down payment on May 23, 2022, the note
requires the Company to make 9 monthly payments of $640.41 over the remaining term of the note. As of September 30, 2022, the obligation
outstanding is $3,842.
Effective
April 5, 2022, the Company entered into a 12-month premium finance agreement in partial consideration for an insurance policy in the
principal amount of $20,931. The note bears an annual interest rate of 10.50%. The Company paid $5,347 as a down payment on April 5,
2022, the note requires the Company to make 9 monthly payments of $1,808.22 over the remaining term of the note. As of September 30,
2022, the obligation outstanding is $7,233.
Effective
July 7, 2022, the Company entered into a 12-month premium finance agreement for an insurance policy in the principal amount of $10,150.
The note bears an annual interest rate of 11%. The Company paid $3,950 as a down payment in July 2022, the note requires the Company
to make 9 monthly payments of $837 over the remaining term of the note. As of September 30, 2022, the obligation outstanding is $5,861.
Effective
July 31, 2022, the Company entered into a 12-month premium finance agreement for an insurance policy in the principal amount of $144,500.
The note bears an annual interest rate of 9.49%. The Company paid $35,803 as a down payment in August 2022, the note requires the Company
to make 10 monthly payments of $11,348 over the remaining term of the note. As of September 30, 2022, the obligation outstanding is $90,784.
Promissory
note
In
January 2020, the Company issued two promissory notes with a principal balance of $500,000 to accredited investors (the “Note Holders”).
The note matures in October 2020 and has an annual rate of interest of 12%. In connection with the issuance of the promissory note, the
Company issued the Note Holders 100,000 common stock purchase warrants with a five-year term from the issuance date, $0.85 per. As of
July 2020, in consideration of the warrants being amended to $0.45 per share with an extended the term from five to a ten-year term,
the maturity date has been extended to December 13, 2020. As of September 30, 2021, the obligation outstanding is $425,000 and $358,996,
net of debt discount of $66,004. As of September 30, 2022, the obligation outstanding is $250,000 and the balance is $200,548, net of
debt discount of $49,452. The Company was notified that the maturity dates on these notes have been extended for the near-term.
In
April 2022, the Company has completed a private placement of a $500,000 unsecured promissory note and 500,000 common share purchase warrants
to an arm’s length lender. The Note becomes due and payable in three months, subject to extension by the Company for an additional
three months upon payment of a $5,000 extension fee to the lender. The Note bears interest at rate of 10% per annum payable at maturity.
The Company may prepay the outstanding principal amount of the obligation together with all accrued and unpaid interest, without penalty,
at any time prior to the maturity date of the note. Each warrant entitles the holder thereof to purchase one common share at a price
of 0.07 for a period of thirty-six (36) months after closing. As of September 30, 2020, the Company made a payment of $250,000 leaving
a balance outstanding of $250,000. A subsequent payment of $250,000 has been tendered satisfying the entire obligation.
In
January 2020, the Company issued two promissory notes with a principal balance of $500,000 to accredited investors (the “Note Holders”).
The notes mature in July 2020 and has an annual rate of interest of 12%. In connection with the issuance of the promissory notes, the
Company issued the Note Holders 100,000 common stock purchase warrants with a five-year term from the issuance date, $0.85 per share.
As of July 2020, in consideration of the warrants being amended to $0.45 per share with an extended the term from five to a ten-year
term, the maturity date has been extended to December 13, 2020. In May 2020, the Company made a principal payment of $20,000. As of September
30, 2021, these obligations were converted into equity.
In
July 2020, the Company’s wholly owned subsidiary in Oregon received loan proceeds of $220,564 pursuant to the Paycheck Protection
Program under the CARES Act. The Loan, which was in the form of a promissory note, dated July 09, 2020, between the Company and Cross
River Bank as the lender, matures on July 09, 2022 and bears interest at a fixed rate of 1% per annum, payable monthly commencing in
six months. Under the terms of the PPP, the principal may be forgiven if the Loan proceeds are used for qualifying expenses as described
in the CARES Act, such as payroll costs, benefits mortgage interest, rent, and utilities. No assurance can be provided that the Company
will obtain forgiveness of the Loan in whole or in part. In addition, details of the PPP continue to evolve regarding which companies
are qualified to receive loans pursuant to the PPP and on what terms, and the Company may be required to repay some or all of the Loan
due to these changes or different interpretations of the PPP requirements. As of September 30, 2021, the obligation outstanding of $220,565
was forgiven and recorded as other income.
The
Company received loan proceeds of $266,820 pursuant to the Paycheck Protection Program under the CARES Act. The Loan, which was in the
form of a promissory note, dated May 1, 2020, between the Company and Transportation Alliance Bank as the lender, matures on May 1, 2022
and bears interest at a fixed rate of 1% per annum, payable monthly commencing in six months. Under the terms of the PPP, the principal
may be forgiven if the Loan proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs, benefits
mortgage interest, rent, and utilities. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or
in part. In addition, details of the PPP continue to evolve regarding which companies are qualified to receive loans pursuant to the
PPP and on what terms, and the Company may be required to repay some or all of the Loan due to these changes or different interpretations
of the PPP requirements. As of September 30, 2021, the obligation outstanding of $266,820 was forgiven and recorded as other income.
The
Company’s related entity received loan proceeds of $245,400 pursuant to the Paycheck Protection Program under the CARES Act. The
Loan, which was in the form of a promissory note, dated June 03, 2020, between the Company and Coastal States Bank as the lender, matures
on June 03, 2022 and bears interest at a fixed rate of 1% per annum, payable monthly commencing in six months. Under the terms of the
PPP, the principal may be forgiven if the Loan proceeds are used for qualifying expenses as described in the CARES Act, such as payroll
costs, benefits mortgage interest, rent, and utilities. No assurance can be provided that the Company will obtain forgiveness of the
Loan in whole or in part. In addition, details of the PPP continue to evolve regarding which companies are qualified to receive loans
pursuant to the PPP and on what terms, and the Company may be required to repay some or all of the Loan due to these changes or different
interpretations of the PPP requirements. As of September 30, 2021, the obligation outstanding of $245,400 was forgiven and recorded as
other income.
The
Company’s subsidiary received loan proceeds of $62,500 pursuant to the Paycheck Protection Program under the CARES Act. The Loan,
which was in the form of a promissory note, dated June 25, 2020, between the Company and First Home Bank as the lender, matures on June
25, 2022, and bears interest at a fixed rate of 1% per annum, payable monthly commencing in six months. Under the terms of the PPP, the
principal may be forgiven if the Loan proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs,
benefits mortgage interest, rent, and utilities. No assurance can be provided that the Company will obtain forgiveness of the Loan in
whole or in part. In addition, details of the PPP continue to evolve regarding which companies are qualified to receive loans pursuant
to the PPP and on what terms, and the Company may be required to repay some or all of the Loan due to these changes or different interpretations
of the PPP requirements. As of September 30, 2021, the obligation outstanding of $62,500 was forgiven and recorded as other income.
The
Company’s subsidiary received loan proceeds of $140,407 pursuant to the Paycheck Protection Program under the CARES Act. The Loan,
which was in the form of a promissory note, dated July 15, 2020, between the Company and Cross River Bank as the lender, matures on December
30, 2020 and bears interest at a fixed rate of 1% per annum, payable monthly commencing in six months. Under the terms of the PPP, the
principal may be forgiven if the Loan proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs,
benefits mortgage interest, rent, and utilities. No assurance can be provided that the Company will obtain forgiveness of the Loan in
whole or in part. In addition, details of the PPP continue to evolve regarding which companies are qualified to receive loans pursuant
to the PPP and on what terms, and the Company may be required to repay some or all of the Loan due to these changes or different interpretations
of the PPP requirements. As of September 30, 2021, the obligation outstanding of $140,407 was forgiven and recorded as other income.
Settlement
payable
As
part of the Agreement and Plan of Merger with Driven Deliveries the Company assumed a settlement payable related to an employment claim
where Driven shall pay certain employees a total of $250,451. This settlement is payable in equal bi-monthly payments over a period of
seventeen (17) Months (36 pay periods), beginning in February 2021. As of September 30, 2021, the settlement payable is presented on
the balance sheet in the amount of $92,045. The balance was paid in full during the fiscal year ended September 30, 2022.
Long-term
debt, mortgages
In
January 2020, the Company refinanced a mortgage payable on property located in Oregon to acquire additional funds. The mortgage bears
interest at 15% per annum. Monthly interest only payments began February 1, 2020, payments will continue each month thereafter until
paid. The entire unpaid balance was due on January 31, 2022, the maturity date of the mortgage, and is secured by the underlying property.
The mortgage terms do not allow participation by the lender in either the appreciation in the fair value of the mortgaged real estate
project or the results of operations of the mortgaged real estate project. The note has been cross guaranteed by the former CEO and Director
of the Company. As of September 30, 2022, the Company paid off the existing debt of $400,000 and procured another mortgage in the amount
of $450,000. This obligation has no personal guarantee; however, a corporate guarantee has been perfected. The new interest is 12% on
a three-year term.
In
March 2020, the Company executed a $400,000 mortgage payable on property located in Oregon to acquire additional funds. The mortgage
bears interest at 11.55% per annum. Monthly interest only payments began May 1, 2020, payments will continue each month thereafter until
paid. The entire unpaid balance was due on April 1, 2022, the maturity date of the mortgage, and is secured by the underlying property.
The Company paid costs of approximately $38,000 to close on the mortgage. The mortgage terms do not allow participation by the lender
in either the appreciation in the fair value of the mortgaged real estate project or the results of operations of the mortgaged real
estate project. The note has been cross guaranteed by the former CEO and Director of the Company. As of September 30, 2022, the obligation
outstanding is $400,000. Subsequently, the Company has exercised its right to extend the maturity and is now due April 1, 2023.
In
March 2020, the Company refinanced a mortgage payable on property located in Oregon to acquire additional funds. The mortgage bears interest
at 15% per annum. Monthly interest only payments began April 1, 2020, payments will continue each month thereafter until paid. The entire
unpaid balance was due on March 31, 2022, the maturity date of the mortgage, and is secured by the underlying property. The mortgage
terms do not allow participation by the lender in either the appreciation in the fair value of the mortgaged real estate project or the
results of operations of the mortgaged real estate project. The note has been cross guaranteed by the former CEO and Director of the
Company. As of September 30, 2022, the Company paid off the existing debt of $700,000 and procured another mortgage in the amount of
$775,000. This obligation has no personal guarantee; however, a corporate guarantee has been perfected. The new interest is 12% on a
two-year term.
In
July 2020, the Company executed a mortgage payable on property located in Oregon to acquire additional funds. The mortgage bears interest
at 14% per annum. Monthly interest only payments began August 1, 2020, payments will continue each month thereafter until paid. The entire
unpaid balance is due on July 31, 2023, the maturity date of the mortgage, and is secured by the underlying property. The mortgage terms
do not allow participation by the lender in either the appreciation in the fair value of the mortgaged real estate project or the results
of operations of the mortgaged real estate project. The note has been cross guaranteed by the former CEO and Director of the Company.
As of September 30, 2022, the obligation outstanding is $200,000.
In
April 2018, the Company received a 37.5% interest in NVD RE Corp. (“NVD”) upon its issuance to NVD of a commitment to contribute
$1.275 million to NVD which included the purchase price of $600,000 and an additional commitment to pay tenant improvement costs of $675,000.
In the year ended September 30, 2019, NVD obtained $300,000 in proceeds from a mortgage on its property. The funds from this mortgage
were advanced to the Company. The advance is undocumented, non-interest bearing and due on demand. As of September 30, 2019, the balance
due totals $300,000. In August 2020, the Company refinanced this obligation and paid the $300,000 balance. The refinanced mortgage term
is 36 months and includes and interest rate of 14% and monthly interest only payments of $4,667. As of September 30, 2022, the balance
due totals $400,000.
The
following is a table of the 5-year runoff of our long-term debt as of September 30:
Schedule of Maturities of Long Term Debt
| |
| | |
2023 | |
$ | 1,000 | |
2024 | |
| 775 | |
2025 | |
| 450 | |
2026 | |
| - | |
2027 | |
| - | |
Thereafter | |
| - | |
Total long-term debt | |
| 2,225 | |
Less current portion of long-term debt: | |
| (1,000 | ) |
Long
term debt | |
$ | 1,225 | |
Finance
liability
In
November 2020, the Company executed a mortgage payable on property located in Mulino, Oregon to acquire additional funds. The
mortgage bears interest at 15%
per annum. The entire unpaid balance is due November 2022, the maturity date of the mortgage, and was secured by the underlying
property. The note was cross guaranteed by the former CEO and Director of the Company. On November 23, 2020, the Company executed a
real estate purchase agreement related to the Mulino Property which included the sale of the property and payoff of the mortgage.
Additionally, the Company entered into a lease agreement whereas the amount of $13,750
required as a rent payment through the lease is being recorded as interest expense and the Company recorded a finance liability of
$1,094,989
related to the lease under the guidance of ASC 842 as a failed sale and leaseback transaction. During the fiscal year ended
September 30, 2022, the Company executed a sale lease back agreement with the Company’s Mulino property, and entered into a
15-year lease with an unrelated third party located in Englewood, CO. The lease requires the Company to pay a starting base rental
fee of $29,167
plus additional estimated triple net charges per month including real estate taxes in which the base rental fee escalates each year
by approximately 2%.
All taxes (including reconciling real estate taxes), maintenance, and utilities are included and paid monthly. This transaction
resulted in net proceeds to the Company in the amount of $1.8
million and a gain on sale of $1.4 million, recorded in other income.
15.
Convertible debt
Canaccord
On
December 27, 2018, the Company entered into an Agency Agreement (the “Agency Agreement”) for a private offering of up to
10,000 convertible debenture special warrants of the Company (the “CD Special Warrants”) for aggregate gross proceeds of
up to CDN$10,000,000 (the “Offering”). The net proceeds of the Offering were used for expansion initiatives and general corporate
purposes. The Company’s functional currency is U.S. dollars.
In
December 2018 and January 2019, the Company issued 3,121 CD Special Warrants in the first closing of the Offering, at a price of CDN
$1,000 per CD Special Warrant, and received aggregate gross proceeds of CDN $3.1 million or $2.3 million USD. In connection with this
offering, the Company issued the agents in such offering 52,430 convertible debenture special warrants (the “Broker CD Special
Warrants”) as partial satisfaction of a selling commission.
On
March 14, 2019, the Company issued 962 CD Special Warrants in the second and final closing of the Offering, at a price of CDN $1,000
per CD Special Warrant, and received aggregate gross proceeds of CDN $1.0 million or $0.7 million USD. In connection with this offering,
the Company issued the agents in such offering 5,600 convertible debenture special warrants (the “Broker CD Special Warrants”)
as partial satisfaction of a selling commission.
The
total aggregate proceeds of the Offering totaled $4.1 million CDN or $3.1 million USD.
Each
CD Special Warrant will be exchanged (with no further action on the part of the holder thereof and for no further consideration) for
one convertible debenture unit of the Company (a “Convertible Debenture Unit”), on the earlier of: (i) the third business
day after the date on which both (A) a receipt (the “Receipt”) for a (final) document (the “Qualification Document”)
qualifying the distribution of the Convertible Debentures (as defined below) and Warrants (as defined below) issuable upon exercise of
the CD Special Warrants has been issued by the applicable securities regulatory authorities in the Canadian jurisdictions in which purchasers
of the CD Special Warrants are resident (the “Canadian Jurisdictions”), and (B) a registration statement (the “Registration
Statement”) registering the resale of the common shares underlying the Convertible Debentures and Warrants has been declared effective
by the U.S. Securities and Exchange Commission (the “Registration”); and (ii) the date that is six months following the closing
of the Offering. The Company has also provided certain registration rights to purchasers of the CD Special Warrants. The CD Special Warrants
were exchanged for Convertible Debenture Units after six months as U.S. and Canadian registrations were not effective at that time.
Each
Convertible Debenture Unit is comprised of CDN $1,000 principal amount 8.0% senior unsecured convertible debenture (each, a “Convertible
Debenture”) of the Company and 167 common share purchase warrants of the Company (each, a “Warrant”). Each Warrant
entitles the holder to purchase one common share of the Company (each, a “Warrant Share”) at an exercise price of CDN $3.90
per Warrant Share for a period of 24 months following the closing of the Offering.
The
Company has agreed to use its best efforts to obtain the Receipt and Registration within six months following the closing of the Offering.
If the Receipt and Registration have not been obtained on or before 5:00 p.m. (PST) on the date that is 120 days following the closing
of the Offering, each unexercised CD Special Warrant will thereafter entitle the holder thereof to receive, upon
the exercise thereof and at no additional cost, 1.05 Convertible Debenture Units per CD Special Warrant (instead of 1.0 Convertible Debenture
Unit per CD Special Warrant). Until the Receipt and Registration have been obtained, securities issued in connection with the Offering
(including any underlying securities issued upon conversion or exercise thereof) will be subject to a six (6)-month hold period from
the date of issue. Since the CD Special Warrants were exchanged for Convertible Debenture Units after six (6) months as U.S. and Canadian
registrations were not effective at that time, the holders received 1.05 Convertible Debenture Units per CD Special Warrant.
The
brokered portion of the Offering (CDN $2.5 million, $1.9 million USD) was completed by a syndicate of agents (collectively, the “Agents”).
The Company paid the Agents a cash commission equal to 7.0% of the gross proceeds raised in the brokered portion of the Offering. As
additional consideration, the Company issued the Agents such number of non-transferable broker convertible debenture special warrants
(the “Broker CD Special Warrants”) as is equal to 7.0% of the number of CD Special Warrants sold under the brokered portion
of the Offering. Each Broker CD Special Warrant shall be exchanged, on the same terms as the CD Special Warrants, into broker warrants
of the Company (the “Broker Warrants”). Each Broker Warrant entitles the holder to acquire one Convertible Debenture Unit
at an exercise price of CDN $1,000, until the date that is 24 months from the closing date of the Offering. The distribution of the Broker
Warrants issuable upon the exchange of the Broker CD Special Warrants shall also be qualified under the Qualification Document and the
resale of the common shares underlying the Broker Warrants will be registered under the Registration Statement. The Company also paid
the lead agent a commission noted above of CDN$157,290, corporate finance fee equal to CDN $50,000 in cash and as to $50,000 in common
shares of the Company at a price per share of CDN$3.00 plus additional expenses of CDN$20,000. In addition, the Company paid the trustees
legal fees of CDN$181,365. In total the Company approx. USD $0.32 million in fees and expenses associated with the offering.
The
issuance of the securities was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended
(the “Securities Act”), for the offer and sale of securities not involving a public offering, Regulation D promulgated under
the Securities Act, Regulation S, in Canada to “accredited investors” within the meaning of National Instrument 45106 and
other exempt purchasers in each province of Canada, except Quebec, and/or outside Canada and the United States on a basis which does
not require the qualification or registration. The securities being offered have not been registered under the Securities Act and may
not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable
exemption from the registration requirements.
The
Convertible Debenture features contain the following embedded derivatives:
|
● |
Conversion
Option - The Convertible Debentures provide the holder the right to convert all or any portion of the outstanding principal into
common shares of the Company at a conversion price of C$3.00 such that 333.33 common shares are issued for each C$1,000 of principal
of Convertible Debentures converted. |
|
● |
Contingent
Put - Upon an Event of Default, the Convertible Debentures settle for cash at the outstanding principal and interest amount (at discretion
of the Indenture Trustee or upon request of Holders of 25% or more of principal of the Convertible Debentures). |
|
● |
Contingent
Put - Upon a Change in Control, the Convertible Debentures settle for cash at the outstanding amount and principal and interest *
105% (where Holder accepts a Change of Control Offer). |
The
conversion option, the contingent put feature upon an Event of Default, and the contingent put feature upon a Change in Control should
be bifurcated and recognized collectively as a compound embedded derivative at fair value at inception and at each quarterly reporting
period.
A
five percent penalty assessed for failure to timely file a registration statement to register the stock underlying the CD special warrants.
The
Company valued the warrants granted using the Black-Scholes pricing model and determined that the value at grant date was approximately
$424,000 USD (this includes the warrants issued as part of the penalty for failure to timely file the required registration statement
under the indenture agreement). The significant assumptions used in the valuation were as follows:
Schedule
of Assumptions Used for Valuation of Warrants
Fair value of underlying common shares | |
$ | 1.78 to $2.10 | |
Exercise price (converted to USD) | |
$ | 2.93 | |
Dividend yield | |
| - | |
Historical volatility | |
| 85 | % |
Risk free interest rate | |
| 1.4% to 1.9 | % |
The
warrants are not indexed to the Company’s own stock under ASC 815, Derivatives and Hedging. As such, the warrants do not meet the
scope exception in ASC 815-10-15-74(a) to derivative accounting and therefore were accounted for as a liability in accordance with the
guidance in ASC 815. The warrant liability was recorded at the date of grant at fair value with subsequent changes in fair value recognized
in earnings each reporting period.
In
April 2020, the Company received approval of the holders Warrant holders of the warrants and the holders debenture holders of the Convertible
Debentures to reprice the convertible securities issued in connection with the Company’s special warrant financing, which closed
on December 27, 2018, and June 14, 2019. The share purchase warrants of the Company issued in connection with the financing will be repriced
to C$1.50
per Common Share and the convertible debentures
of the Company issued in connection with the financing will be repriced to C$1.15
per common share. Additionally, the Debenture
holders have approved the following amendments to the terms of the convertible debentures: (i) an extension to the maturity date of the
convertible debentures to three years from the date of issuance; and (ii) an amendment to permit the Company to force the conversion
of the principal amount of the then outstanding convertible debentures and any accrued and unpaid interest thereof at the new conversion
price on not less than June days’ prior written notice if the closing trading price of the shares of common stock of the Company’s
common shares exceeds C$1.90
for a period of 10 consecutive trading days on
the CSE. The Warrant holders have also approved the inclusion of an early acceleration feature in accordance with the policies of the
Canadian Securities Exchange, permitting the Company to accelerate the expiry date of the warrants should the closing trading price of
the Common Shares exceed C$1.87
for a period of 10 consecutive trading days on
the CSE.
In
June 2022, the Company received approval of the holders Warrant holders of the warrants and the holders debenture holders of the
Convertible Debentures to reprice the convertible securities issued in connection with the Company’s special warrant
financing, which initially closed on December 27, 2018, and June 14, 2019. The share purchase warrants of the Company issued in
connection with the financing will be repriced to C$0.20
per Common Share and the convertible debentures of the Company issued in connection with the financing will be repriced to C$0.10
per common share. Additionally, the Debenture holders have approved the following amendments to the terms of the convertible
debentures: (i) an extension to the maturity date of the convertible debentures to three years ; and (ii) an amendment to permit the
Company to force the conversion of the principal amount of the then outstanding convertible debentures and any accrued and unpaid
interest thereof at the new conversion price on not less than 30 days’ prior written notice if the closing trading price of
the shares of common stock of the Company’s common shares exceeds C$0.80
for a period of 10 consecutive trading days on the CSE, (iii) the payment of 5%
of the principle amount. Share purchase warrants of the Company were issued in connection this repricing at 167 common share
warrants for each $1,000
debenture unit held. A debt discount of $1.2 million was recorded and will be amortized over the remaining life of the convertible
debt, and as part of the modification of convertible debt. This transaction was accounted for as extinguishment of debt which
resulted in a gain of $803 thousand. As of September 30, 2022, the convertible debt related to the above debentures was $1.5 million
and $2.9
million, net of a debt discount of $1.1 million and $0, respectively.
The
table below shows the warrant liability and embedded derivative liability recorded in connection with the Canaccord convertible notes
and the subsequent fair value measurement for the period ended September 30, 2022, in USD, (in thousands):
Schedule of Warrant Liability and Embedded Derivative Liability
| |
Warrant Liability | | |
Derivative Liability | |
Balance as of September 30, 2021 | |
$ | - | | |
$ | - | |
Modification of debentures | |
| - | | |
| 339 | |
Change in fair value | |
| - | | |
| 31 | |
Balance as of September 30, 2022 | |
$ | - | | |
$ | 370 | |
16.
Fair Value Measurements
In
accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the outstanding warrants
and certain embedded conversion feature associated with convertible debt on a recurring basis to determine the fair value of the liability.
ASC 820 also establishes a hierarchy categorizing inputs into three levels used to measure and disclose fair value. The hierarchy gives
the highest priority to quoted prices available in active markets and the lowest priority to unobservable inputs. An explanation of each
level in the hierarchy is described below:
Level
1 – Unadjusted quoted prices in active markets for identical instruments that are accessible by the Company on the measurement
date
Level
2 – Quoted prices in markets that are not active or inputs which are either directly or indirectly observable
Level
3 – Unobservable inputs for the instrument requiring the development of assumptions by the Company
The
following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy
as of September 30, 2021 (in thousands):
Schedule of Liabilities Measured at Fair Value on a Recurring Basis
| |
| | |
| | |
| | |
| |
| |
Fair value measured at September 30, 2022 | |
| |
| | |
Quoted prices | | |
Significant other | | |
Significant | |
| |
| | |
in active
markets | | |
observable
inputs | | |
unobservable inputs | |
| |
Fair value | | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | |
Warrant liability | |
$ | 55 | | |
$ | - | | |
$ | - | | |
$ | 55 | |
Embedded derivative liability | |
| 370 | | |
| - | | |
| - | | |
| 370 | |
Total fair value | |
$ | 425 | | |
$ | - | | |
$ | - | | |
$ | 425 | |
There
were no transfers between Level 1, 2 or 3 during the year ended September 30, 2022.
The
following table presents changes in Level 3 liabilities measured at fair value for the year ended September 30, 2022. Both observable
and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.
Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable
to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities)
inputs (in thousands).
Schedule of Level 3 Liabilities Measured at Fair Value
| |
| | |
Embedded | | |
| |
| |
Warrant Liability | | |
Derivative Liability | | |
Total | |
Balance – September 30, 2020 | |
$ | 257 | | |
$ | 592 | | |
$ | 849 | |
Warrants granted for stock-based compensation | |
| 59 | | |
| - | | |
| 59 | |
Warrants issued pursuant to acquisition (see Note 9) | |
| 9,000 | | |
| - | | |
| 9,000 | |
Issuance of convertible notes | |
| (66 | ) | |
| (15 | ) | |
| (81 | ) |
Change in fair value | |
| (2,401 | ) | |
| (577 | ) | |
| (2,978 | ) |
Cancellation of warrants pursuant to settlement agreement | |
| (4,572 | ) | |
| - | | |
| (4,572 | ) |
| |
| | | |
| | | |
| | |
Balance - September 30, 2021 | |
$ | 2,277 | | |
$ | - | | |
$ | 2,277 | |
Warrants granted | |
| 105 | | |
| - | | |
| 105 | |
Modification of debentures | |
| - | | |
| 339 | | |
| 339 | |
Change in fair value | |
| (2,327 | ) | |
| 31 | | |
| (2,296 | ) |
| |
| | | |
| | | |
| | |
Balance - September 30, 2022 | |
$ | 55 | | |
$ | 370 | | |
$ | 425 | |
A
summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s
warrant liabilities and embedded conversion feature that are categorized within Level 3 of the fair value hierarchy as of September 30,
2022, and 2021 is as follows:
Summary of Weighted Average Significant Unobservable Inputs
| |
Warrant Liability | |
| |
As of September 30, | | |
As of September 30, | |
| |
2022 | | |
2021 | |
Strike price | |
$ | 0.49 | | |
$ | 0.48 | |
Contractual term (years) | |
| 1.43 | | |
| 2.57 | |
Volatility (annual) | |
| 100 | % | |
| 74 | % |
Risk-free rate | |
| 4.1 | % | |
| 1.0 | % |
Dividend yield (per share) | |
| 0 | % | |
| 0 | % |
| |
Embedded Derivative Liability | |
| |
As of September 30, | | |
As of September 30, | |
| |
2022 | | |
2021 | |
Strike price | |
$ | 0.10 | | |
$ | 0.90 | |
Contractual term (years) | |
| 2.8 | | |
| 0.8 | |
Volatility (annual) | |
| 141 | % | |
| 55 | % |
Risk-free rate | |
| 4.00 | % | |
| 0.08 | % |
Dividend yield (per share) | |
| 0.00 | % | |
| 0.00 | % |
Credit spread | |
| 14% to 16 | % | |
| 14% to 16 | % |
The
Company used a lattice based trinomial model developed by Tsiveriotis, K. and Fernades in which the three lattices incorporate (1) the
Company’s underlying common stock price; (2) the value of the debt components of the convertible notes; and (3) the value of the
equity component of the convertible notes. The main drivers of sensitivity for the model are volatility and the credit spread. The model
used will vary by approximately 1.5% for a 4% change in volatility and will vary by less than 1% for each 1% change in credit spread.
17.
Income Taxes
The
income tax expense (benefit) consisted of the following for the fiscal year ended September 30, 2022 and 2021:
Schedule of Income Tax Expenses (Benefit)
| |
| September 30, | | |
| September 30, | |
| |
| 2022 | | |
| 2021 | |
Total current | |
$ | - | | |
$ | - | |
Total deferred | |
| - | | |
| - | |
Income tax expense (benefit) | |
$ | - | | |
$ | - | |
Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes.
The
following is a reconciliation of the expected statutory federal income tax provision to the actual income tax benefit for the fiscal
year ended September 30, 2022 and 2021:
Schedule of Reconciliation of Statutory Federal Income Tax Provision to Actual Income Tax Benefit
| |
September 30, | | |
September 30, | |
| |
2022 | | |
2021 | |
Federal statutory rate | |
$ | (4,382 | ) | |
$ | (16,152 | ) |
Permanent timing differences | |
| 3,272 | | |
| 12,165 | |
Other | |
| (58 | ) | |
| - | |
Change in valuation allowance | |
| 1,168 | | |
| 3,987 | |
Income tax expense | |
$ | - | | |
$ | - | |
For
the years ended September 30, 2022 and 2021, the expected tax benefit, temporary timing differences and long-term timing differences
are calculated at the 25% statutory rate.
Significant
components of the Company’s deferred tax assets and liabilities were as follows for the fiscal year ended September 30, 2022 and
2021:
Schedule of Deferred Tax Assets and Liabilities
| |
September 30, | | |
September 30, | |
| |
2022 | | |
2021 | |
Deferred tax assets: | |
| | | |
| | |
Net operating loss carryforwards | |
$ | 10,110 | | |
$ | 8,454 | |
Equity based compensation | |
| 3,045 | | |
| 3,192 | |
Impairment of investments and other property | |
| 2,011 | | |
| 2,362 | |
Total deferred tax assets | |
| 15,166 | | |
| 14,008 | |
| |
| | | |
| | |
Deferred tax liabilities | |
| | | |
| | |
Depreciation | |
| 39 | | |
| 49 | |
Total deferred tax liabilities | |
| 39 | | |
| 49 | |
| |
| | | |
| | |
Net deferred tax assets | |
| 15,127 | | |
| 13,959 | |
Less valuation allowance | |
| (15,127 | ) | |
| (13,959 | ) |
Net deferred tax assets (liabilities) | |
$ | - | | |
$ | - | |
At
September 30, 2022, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $40 million.
The federal and state net operating loss carryforwards will expire beginning in 2038.
During
the fiscal year ended September 30, 2022 and 2021 the Company recognized no amounts related to tax interest or penalties related to uncertain
tax positions. The Company is subject to taxation in the United States and various state jurisdictions. The Company currently has no
years under examination by any jurisdiction.
18.
Shareholders’ Equity
In
2016, the Company adopted a plan to allow the Company to compensate prospective and current employees, directors, and consultants through
the issuance of equity instruments of the Company. The plan has an effective life of 10 years. The plan is administered by the board
of directors of the Company until such time as the board transfers responsibility to a committee of the board. The plan is limited to
issuing common shares of the Company up to 15% of the total shares then outstanding. No limitations exist on any other instruments issuable
under the plan. In the event of a change in control of the Company, all unvested instruments issued under the plan become immediately
vested.
Pursuant
to the shareholders meeting on June 25, 2021, the Company has amended its certificate of incorporation to increase the number of authorized
Company Common Shares from 300,000,000 to 750,000,000.
Preferred
shares
The
Company had two series of preferred shares designated with no preferred shares issued and outstanding as of September 30, 2022, and September
30, 2021.
Common
shares
During
the year ended September 30, 2022, the Company issued 3,223,611 shares of its common stock related to a stock purchase agreement for
cash of $285,000.
During
the year ended September 30, 2022, the Company issued 130,000 shares of its common stock related to various consulting agreements for
a fair value of approximately $30,000.
During
the year ended September 30, 2022, the Company issued 3,137,500 shares of its common stock valued at $313,000 as stock-based compensation.
During
the year ended September 30, 2022, the Company converted $13,000 of principal balance related to convertible debt in exchange for 289,750 shares
of the company’s common stock. The Company also issued 1,751,186 common shares in satisfaction of interest payments owed of $121,000.
During
the year ended September 30, 2022, the Company received 11,506,700
shares of its common stock related to a share exchange agreement pursuant to the divestiture of Driven (see Note 3).
During
the year ended September 30, 2021, the Company issued 3,914,509 shares of its common stock valued at $1,675,000 as stock-based compensation.
During
the year ended September 30, 2021, the Company issued 4,790,070 shares of its common stock related to various consulting agreements for
a fair value of approximately $2,032,000 with a price per share ranging from $0.29 to $0.51.
During
the year ended September 30, 2021, the Company sold 1,465,117 shares of its common stock for total cash received of $630,000.
During
the year ended September 30, 2021, the Company cancelled 525,400 common shares related to convertible notes.
During
the year ended September 30, 2021, the Company cancelled 58,140 common shares related to a subscription agreement.
During
the year ended September 30, 2021, the Company converted $309,121 of its accrued interest related to convertible debt in exchange for
553,417 shares of the company’s common stock. The Company also issued 293,700 common shares in satisfaction of rent payments owed
of $117,480.
During
the year ended September 30, 2021, as part of the Agreement and Plan of Merger with Driven Deliveries the Company issued 101,968,944
common shares.
During
the year ended September 30, 2021, the Company issued 300,000 shares of its common stock with a fair value of $210,000 on behalf of its
Michigan joint venture partner into escrow pursuant to a security agreement related to the commercial lease.
During
the year ended September 30, 2021, the Company converted $4,913,000 of principal balance related to convertible debt in exchange for
9,480,259 shares of the company’s common stock.
During
the year ended September 30, 2021, the Company issued 500,000 shares of its common stock in connection with a settlement agreement for
settlement liability of $5,439,855.
During
the year ended September 30, 2021, the Company raised $4,892,000 for the issuance of 5,322,136 shares of its common stock in connection
with a private placement memorandum.
During
the year ended September 30, 2021, the Company issued 10,000 shares of its common stock in connection with the exercise of the company’s
stock option plan.
During
the year ended September 30, 2021, the Company issued 90,909 shares of its common stock valued at $40,000 in connection with commission
expense.
During
the year ended September 30, 2021, the Company cancelled 694,233 common shares related to investment.
During
the year ended September 30, 2021, the Company issued 19,276,340 shares of its common stock valued at $7,919 million pursuant to its
Canadian prospectus.
During
the year ended September 30, 2021, the Company issued 8,209,178 shares of its common stock in connection with an asset acquisition valued
at $2,380,661.
During
the year ended September 30, 2021, the Company raised $2,869,889 for the issuance of 6,833,069 common shares pursuant to Driven Deliveries,
Inc. S1 registration.
19.
Stock Based Compensation
Stock
Options
The
fair value of the Company’s common stock was based upon the publicly quoted price on the date that the final approval of the awards
was obtained. The Company does not expect to pay dividends in the foreseeable future so therefore the expected dividend yield is 0%.
The expected term for stock options granted with service conditions represents the average period the stock options are expected to remain
outstanding and is based on the expected term calculated using the approach prescribed by the Securities and Exchange Commission’s
Staff Accounting Bulletin for “plain vanilla” options. The expected term for stock options granted with performance and/or
market conditions represents the period estimated by management by which the performance conditions will be met. The Company obtained
the risk-free interest rate from publicly available data published by the Federal Reserve. The Company uses a methodology in estimating
its volatility percentage from a computation that was based on a comparison of average volatility rates of similar companies to a computation
based on the standard deviation of the Company’s own underlying stock price’s daily logarithmic returns.
The
fair value of options granted during the years ended September 30, 2022, and 2021 were estimated using the following weighted-average
assumptions:
Options:
Schedule of Fair Value of Options Granted
| |
For the Years Ended September 30, | |
| |
2022 | | |
2021 | |
Exercise price | |
$ | 0.07 | | |
$ | 0.28 | |
Expected term (years) | |
| 2.52 | | |
| 4.39 | |
Expected stock price volatility | |
| 124 | % | |
| 74 | % |
Risk-free rate of interest | |
| 2.42 | % | |
| 0.98 | % |
Expected dividend rate | |
| 0 | % | |
| 0 | % |
A
summary of option activity under the Company’s stock option plan for the year ended September 30, 2022 is presented below:
Schedule of Stock Option Activity
| |
Number of Shares | | |
Weighted Average Exercise Price | | |
Total Intrinsic Value | | |
Weighted Average Remaining Contractual Life (in years) | |
Outstanding as of October 1, 2020 | |
| 5,572,916 | | |
$ | 1.77 | | |
$ | - | | |
| 2.21 | |
Granted | |
| 1,125,000 | | |
| 0.28 | | |
$ | 54 | | |
| 4.39 | |
Outstanding as of September 30, 2021 | |
| 6,697,916 | | |
$ | 1.07 | | |
$ | - | | |
| 2.09 | |
Granted | |
| 1,500,000 | | |
| 0.07 | | |
$ | - | | |
| 3.00 | |
Expired/cancelled | |
| (2,242,231 | ) | |
| (0.67 | ) | |
$ | - | | |
| - | |
Outstanding as of September 30, 2022 | |
| 5,955,685 | | |
$ | 1.07 | | |
$ | - | | |
| 2.90 | |
Options vested and exercisable | |
| 5,518,185 | | |
$ | 0.03 | | |
$ | - | | |
| 2.60 | |
Estimated
future stock-based compensation expense relating to unvested stock options was nominal as of September 30, 2022, and 2021. Weighted
average remaining contractual life of the options is 2.60
years. The options had no intrinsic value as of September 30, 2022.
Restricted
Stock
A
summary of employee restricted stock activity for years ended September 30, 2022 and 2021 are presented below:
Schedule of
Employee Restricted Stock Activity
| |
Number of Shares | | |
Weighted Average Exercise Price | |
Outstanding as of October 1, 2020 | |
| 2,471,317 | | |
| 1.57 | |
Granted (1) | |
| 3,914,509 | | |
| 0.96 | |
Outstanding as of September 30, 2021 | |
| 6,385,826 | | |
| 0.93 | |
Granted | |
| 2,637,500 | | |
| 0.11 | |
Outstanding as of September 30, 2022 | |
| 9,023,326 | | |
$ | 0.69 | |
A
summary of non-employee restricted stock activity under the Company’s for years ended September 30, 2022 and 2021 are presented
below:
Schedule of
Non Employee Restricted Stock Activity
| |
Number of Shares | | |
Weighted Average Exercise Price | |
Outstanding as of September 30, 2020 | |
| 3,859,178 | | |
| 1.72 | |
Granted | |
| 5,058,370 | | |
| 0.58 | |
Outstanding as of September 30, 2021 | |
| 8,917,548 | | |
| 0.99 | |
Granted | |
| 630,000 | | |
| 0.67 | |
Outstanding as of September 30, 2022 | |
| 9,547,548 | | |
$ | 0.97 | |
Warrants
A
summary of the status of the Company’s outstanding warrants as of September 30, 2022 and 2021 and changes during the year then
ended are presented below:
Schedule of
Warrants Outstanding
| |
Number of Warrants | | |
Weighted Average Exercise Price | | |
Remaining Contractual Term | |
Outstanding as of September 30, 2020 | |
| 5,114,733 | | |
$ | 2.13 | | |
| 1 | |
Warrants granted – equity | |
| 32,666,266 | | |
| 0.53 | | |
| 2 | |
Warrants expired – equity | |
| (114,300 | ) | |
| 2.50 | | |
| 0 | |
Warrants granted – liability | |
| 30,299,134 | | |
| 0.45 | | |
| 3.04 | |
Warrants expired – liability | |
| (5,000,000 | ) | |
| 0.20 | | |
| 1.51 | |
Outstanding as of September 30, 2021 | |
| 62,965,833 | | |
| 0.47 | | |
| 1.23 | |
Warrants exercised – equity | |
| (1,000,000 | ) | |
| 0.04 | | |
| - | |
Warrants granted – equity | |
| 4,173,612 | | |
| 0.10 | | |
| 2.00 | |
Warrants expired – equity | |
| (972,117 | ) | |
| 0.10 | | |
| - | |
Warrants granted – liability | |
| 615,731 | | |
| 0.12 | | |
| 2.00 | |
Outstanding as of September 30, 2022 | |
| 65,783,059 | | |
| 0.49 | | |
| 1.43 | |
Stock-based
Compensation Expense
Stock-based
compensation expense for the years ended September 30, 2022, and 2021 was comprised of the following (in thousands):
Schedule of Stock-based Compensation Expenses
| |
2022 | | |
2021 | |
| |
Years Ended September 30, | |
| |
2022 | | |
2021 | |
Restricted stock awards | |
$ | 296 | | |
$ | 1,935 | |
Stock options | |
| 454 | | |
| 279 | |
Warrants | |
| 263 | | |
| 59 | |
Accrued stock compensation | |
| - | | |
| - | |
Total stock-based compensation | |
$ | 1,013 | | |
$ | 2,273 | |
20.
Commitments and contingencies
As
noted earlier in Note 1, the Company, engages in a business that constitutes an illegal act under the laws of the United States Federal
Government. This raises several possible issues which may impact the Company’s overall operations, not the least of which are related
to traditional banking and other key operational risks. Since cannabis remains illegal on the federal level, and most traditional banks
are federally insured, those financial institutions will not service cannabis businesses. In states where medical or recreational marijuana
is legal, dispensary owners, manufacturers, and anybody who “touches the plant,” continue to face a host of operational hurdles.
While local, state-chartered banks and credit unions now accept cannabis commerce, there remains a reluctance by traditional banks to
do business with them. Aside from a huge inconvenience and the need to find creative ways to manage financial flow, payroll logistics,
and payment of taxes, his also poses tremendous risks to controls as a result of operating a lucrative business in cash. This lack of
access to traditional banking may inhibit industry growth. For the year ended September 30, 2022, the Company’s has accounts with
a Florida bank and several credit unions located in Washington and California.
Despite
the uncertainties surrounding the Federal government’s position on legalized marijuana, the Company does not believe these risks
will have a substantive impact on its planned operations in the near term.
The
Company executed an Agency Agreement and in consideration of the services rendered by the Agent and in connection with the Offering,
the Company has agreed to pay the Agent, on the Closing Date a commission equal to 7% of the gross proceeds of the Offering (including
in respect of any exercise of the Over-Allotment Option, if any) payable in cash (the “Agent’s Commission”),
subject to a reduced fee equal to 1% for Units sold to certain purchasers designated by the Company on a president’s list
(the “President’s List”). In addition the Agent will receive a number of share purchase warrants (the
“Broker Warrants”) to purchase up to that number of shares of common stock of the Company (each, a “Broker
Share”) that is equal to 7% of the aggregate number of Units issued under the Offering (including any Additional Units
(as hereinafter defined) issued upon exercise of the Over-Allotment Option, if any), subject to a reduced number of Broker Warrants
equal to 3.5% of the Units sold to purchasers on the President’s List, at an exercise price of $0.55 CAD per Broker Share,
exercisable for a period of 24 months following the Closing Date. Pursuant to the Agency Agreement, the Company also agreed to pay to
the Agent a corporate finance fee of $100,000 CAD (the “Corporate Finance Fee”), such Corporate Finance Fee to be
payable as to $50,000 CAD in cash and as to $50,000 CAD by the issuance of 90,909 shares of common stock of the Company (the “Corporate
Finance Fee Shares”) at the Offering Price. After deducting the Agent’s Commission (assuming no President’s
List purchasers), the estimated expenses of the Offering of $350,000 CAD and the cash portion of the Corporate Finance Fee, which
will be paid out of the general funds of the Company. The Company has also granted to the Agent an over-allotment option (the “Over-Allotment
Option”), exercisable in whole or in part, at the Agent’s sole discretion, to purchase up to an additional 15% of the
number of Units sold pursuant to the Offering, being up to an additional 2,590,909 Units in the case of the Maximum Offering (the “Additional
Units”), each Additional Unit to be comprised of one Unit Share and one Warrant, at the Offering Price to cover the Agent’s
over-allocation position, if any, and for market stabilization purposes. The Over-Allotment Option is exercisable, in whole or in part,
at any time or times until the date that is 30 days immediately following the Closing Date. A purchaser who acquires Additional Units
forming part of the Agent’s over-allocation position acquires such Additional Units under this Prospectus, regardless of whether
the over-allocation position is ultimately filled through the exercise of the Over-Allotment Option or secondary market purchases. If
the Over-Allotment Option is exercised in full, the total Price to the Public, Agent’s Commission and Net Proceeds to the Company
(before deducting expenses of the Offering and assuming no President’s List purchasers) will be $9,200,000 CAD, $644,000 CAD and
$8,556,000 CAD, respectively, in the case of the Minimum Offering and, $10,925,000 CAD, $764,750 CAD and $10,160,250 CAD, respectively,
in the case of the Maximum Offering. Pursuant to the terms of the Agency Agreement, all subscription funds received from subscribers
will be retained in trust by the Agent until the Minimum Offering is obtained. Once the Minimum Offering has been obtained, the sale
of the Units shall be completed in accordance with the Agency Agreement. To date, all funds have been subscribed and will be held in
escrow for final approval. Additionally, the Company entered into an offering led by Canaccord Genuity Corp. (the “Agent”)
on a ‘commercially reasonable efforts’ basis and consisted of the sale of 16,926,019 Units (including 1,471,291 Units pursuant
to the partial exercise of the over-allotment option by the Agent) at a price of C$0.55 per Unit for aggregate gross proceeds of C$10,309,210
(including C$809,210.05 pursuant to the partial exercise of the over-allotment option by the Agent). Each Unit is comprised of one share
in the common stock of the Company (each a “Unit Share”) and one share purchase warrant of the Company (each, a “Warrant”).
Each Warrant is exercisable to acquire one share in the common stock of the Company (each, a “Warrant Share”) until April
23, 2023, at a price per Warrant Share of C$0.68, subject to adjustment in certain events. The net proceeds raised under the Offering
will be used for working capital and in furtherance of some or all of the business objectives described in the final short form prospectus
of the Company dated April 19, 2021 (the “Final Prospectus”). The Company has given notice to list the Unit Shares and the
Warrant Shares on the Canadian Securities Exchange (the “Exchange”). Listing will be subject to the Company fulfilling all
of the requirements of the Exchange. Concurrent with the Offering, the Company also conducted a non-brokered offering in the United States
of 972,092 units of the Company at a price of US$0.43 per unit for aggregate gross proceeds of approximately US$420,000 under the terms
of a registration statement on Form S-1, as amended, filed with the United States Securities and Exchange Commission under the U.S. Securities
Act on January 5, 2021.
Legal
Proceedings
D.H.
Flamingo, Inc. v. Department of Taxation, et. al.
On
February 27, 2020, a subsidiary of the Company (YMY Ventures, LLC) was served with a Summons and Second Amended Complaint in a matter
pending in the District Court of Clark County Nevada (Case # A-19-787004-B) which is styled “D.H. Flamingo, Inc. v. Department
of Taxation, et. al.” (the DOT Litigation”). In this matter, the Plaintiff is alleging that certain parties (including
YMY Ventures, LLC) received Conditional Recreational Marijuana Establishment Licenses, while certain other parties (including Plaintiff)
were denied licenses. In the matter, Plaintiff seeks declaratory relief, injunctive relief, relief from violation of procedural and substantive
due process, violation of equal protection, unjust enrichment, judicial review of the entire matter, together with a Petition for Writ
of Mandamus. The Plaintiff seeks damages in an unspecified amount. Thereafter, on April 20, 2020, YMY Ventures, LLC filed a Notice of
Non-Participation and Request for Dismissal. This matter has now been fully resolved
without any financial exposure on the part of the Company.
Chris
Hass, et al. vs Brian Hayek, et al.
Plaintiffs
filed their initial complaint in the instant action on May 22, 2020. Plaintiffs filed the operative first amended complaint on
August 18, 2020. On March 28, 2022, Plaintiffs obtained a stipulated judgment in this action in the amount of $349,876.69
against Defendants Driven Deliveries, Brian Hayek (“Hayek”), and Christian Schenk (“Schenk”) (collectively,
“Defendants”). (3/28/22 Judgment.) Plaintiffs declare that during the litigation of the instant action, Baumgartner
negotiated the essential terms of a settlement with Driven Deliveries’ President, Salvador
Villanueva(“Villanueva”), and Villanueva represented to Baumgartner that he was in charge of the litigation and a deal
could be worked out between the two of them to resolve the case. Plaintiffs declare the basic terms of a settlement were reached
between Villanueva and Baumgartner, and Plaintiffs signed a settlement agreement (“Settlement Agreement”) on November
24, 2020. Defendants, including Hayek, signed the Agreement on November 30, 2020. Plaintiffs declare they signed the Settlement
Agreement because they knew Driven Deliveries was merging with Stem. Plaintiffs declare that for this reason, they made sure to
state in the Settlement Agreement that in the event of a merger between Driven Deliveries and Stem, Stem would be bound by the
Settlement Agreement and would be named on the Judgment. Plaintiffs also declare that when they signed the Settlement Agreement,
they relied on the fact Hayek, Stem’s new Agreement to bind his new company. Plaintiffs declare Defendants made payments on
the Settlement Agreement until November 2021, when payments stopped. Plaintiffs declare the settlement checks were mostly written by
Villanueva. Plaintiffs declare that shortly after they signed the Settlement Agreement, Driven Deliveries officially completed its
merger with Stem, and all of Plaintiffs’ shares in Driven Deliveries were converted to shares of Stem. In January 2022,
Villanueva listed himself as President, Secretary, and Treasurer of Driven Deliveries. Plaintiffs filed the instant motion on
September 8, 2022. On October 3, 2022, Defendant Driven Deliveries filed its notice of bankruptcy proceedings, and the Court ordered
a stay as to Driven Deliveries. On October 20, 2022, nonparty Stem filed its opposition. On October 26, 2022, Plaintiffs filed their
reply. At the November 2, 2022 hearing on the instant motion, the Court requested Plaintiffs and Stem submit supplemental briefs on
which state law to apply regarding successor liability.
Under
California law, Stem, as Driven Deliveries’ prior parent company was legally required to assume Driven Deliveries’ debt
to Plaintiffs. If a domestic corporation owns all the outstanding shares, or owns less than all the outstanding shares but at least
90 percent of the outstanding shares of each class, of a corporation or corporations, domestic or foreign, the merger of the
subsidiary corporation or corporations into the parent corporation or the merger into the subsidiary corporation of the parent
corporation and any other subsidiary corporation or corporations, may be effected by a resolution or plan of merger adopted and
approved by the board of the parent corporation and the filing of a certificate of ownership as provided in subdivision . The
resolution or plan of merger shall provide for the merger and shall provide that the surviving corporation assumes all the
liabilities of each disappearing corporation and shall include any other provisions required by this section. Stem’s S-4
Statement to the SEC states, “Driven is surviving the merger as a wholly owned subsidiary of Stem (the ‘Merger’).
Stem, together with Driven following the Merger, is referred to herein as the combined company. Following the completion of the
Merger, Stem will also assume Driven’s outstanding net indebtedness.” Plaintiffs argue that while the merger with Stem
was pending, Driven and Stem’s COO, Brian Hayek agreed to be bound by California law in executing the Settlement Agreement.
Accordingly, applying California law, Stem assumed Dirven’s liability to Plaintiffs. Accordingly, Plaintiffs have demonstrated
Stem is Driven Deliveries’ successor in interest. In the interest of justice this Court grants Plaintiffs’ motion to
amend judgment to add nonparty Stem Holdings Inc. as an additional defendant.
Additionally,
the Company is subject from time to time to litigation, claims and suits arising in the ordinary course of business.
21.
Subsequent events
In
November 2022, the Company completed a private placement of a $250,000 unsecured promissory note and 250,000 common share purchase warrants
to an arm’s length lender. The Note becomes due and payable in three months, subject to extension by the Company for an additional
three months upon payment of a $5,000 extension fee to the lender. The Note bears an interest rate of 10% per annum payable at maturity.
The Company may prepay the outstanding principal amount of the obligation together with all accrued and unpaid interest, without penalty,
at any time prior to the maturity date of the note. Each warrant entitles the holder thereof to purchase one common share at a price
of $0.05 for a period of thirty-six (36) months after closing.
In
January 2023, the Company has partially converted a $250,000 unsecured convertible promissory note and issued 7,352,941 common shares
to convert 50% of the note. The remaining balance is recorded at $125,000.
In
January 2023, the Company has executed a $250,000 unsecured convertible promissory note and 500,000 common share purchase warrants to
an arm’s length lender. The Note becomes due and payable on March 31, 2023 and is subject to a voluntary conversion by the Holder
at the conversion rate of $0.01 a share. The Note bears an interest rate of 12% per annum payable at maturity. Each warrant entitles
the holder thereof to purchase one common share at a price of $0.005 for a period of thirty-six (36) months after closing.
In
January 2023, pursuant to an Oregon Real Estate Agreement, the Company sold its ownership interest in Never Again 2, LLC. The purchase
price for this land was $275,000 and did not include the license.